0001144204-17-057623.txt : 20171109 0001144204-17-057623.hdr.sgml : 20171109 20171109141040 ACCESSION NUMBER: 0001144204-17-057623 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171109 DATE AS OF CHANGE: 20171109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alliqua BioMedical, Inc. CENTRAL INDEX KEY: 0001054274 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 582349413 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36278 FILM NUMBER: 171190084 BUSINESS ADDRESS: STREET 1: 1010 STONY HILL ROAD STREET 2: SUITE 200 CITY: YARDLEY STATE: PA ZIP: 19067 BUSINESS PHONE: 215-702-8550 MAIL ADDRESS: STREET 1: 1010 STONY HILL ROAD STREET 2: SUITE 200 CITY: YARDLEY STATE: PA ZIP: 19067 FORMER COMPANY: FORMER CONFORMED NAME: Alliqua, Inc. DATE OF NAME CHANGE: 20101222 FORMER COMPANY: FORMER CONFORMED NAME: HEPALIFE TECHNOLOGIES INC DATE OF NAME CHANGE: 20030529 FORMER COMPANY: FORMER CONFORMED NAME: ZETA CORP DATE OF NAME CHANGE: 20030219 10-Q 1 tv478458_10q.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 10-Q

 

(Mark One)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the quarterly period ended: September 30, 2017
   
OR
   
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________  to  ___________

 

Commission file number: 001-36278

 

Alliqua BioMedical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   58-2349413
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number)
     

1010 Stony Hill Road

Yardley, PA

   19067
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 702-8550  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ  No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
       
Non-accelerated filer ¨ (Do not check if a smaller reporting company)  
       
Smaller reporting company þ Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ¨ No þ

 

As of November 8, 2017, the registrant had 4,986,034 shares of common stock outstanding.

 

 

 

 

 

 

ALLIQUA BIOMEDICAL, INC.

 

TABLE OF CONTENTS

 

  PART I – FINANCIAL INFORMATION  
     
ITEM 1. Financial Statements  
  Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016 3
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016 4
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016  5
  Notes to Condensed Consolidated Financial Statements 6
     
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk 24
ITEM 4. Controls and Procedures 24
     
  PART II – OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 24
ITEM 1A.  Risk Factors 25
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
ITEM 3.   Defaults Upon Senior Securities  25
ITEM 4. Mine Safety Disclosures 25
ITEM 5.  Other Information 26
ITEM 6. Exhibits 26
     
Signatures   26

 

 2 

 

 

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

 

ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   September 30,   December 31, 
   2017   2016 
   (Unaudited)     
ASSETS:          
Current Assets:          
Cash and cash equivalents  $2,106   $5,580 
Accounts receivable, net   2,926    2,453 
Inventory, net   1,985    2,153 
Prepaid expenses and other current assets   296    735 
Current assets of discontinued operations   464    857 
Total current assets   7,777    11,778 
Improvements and equipment, net   1,692    2,092 
Intangible assets, net   23,202    26,604 
Goodwill, net   11,959    11,959 
Other assets   173    173 
Assets of discontinued operations - noncurrent   -    1,893 
Total assets  $44,803   $54,499 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities:          
Accounts payable  $1,603   $2,614 
Accrued expenses and other current liabilities   3,876    5,224 
Contingent consideration, current   -    675 
Senior secured term loan, net   10,736    11,541 
Warrant liability   419    20 
Current liabilities of discontinued operations   37    60 
Total current liabilities   16,671    20,134 
Contingent consideration, long-term   -    1,141 
Deferred tax liability   758    749 
Other long-term liabilities   316    385 
Total liabilities   17,745    22,409 
           
Commitments and Contingencies          
           
Stockholders' Equity          
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding   -    - 
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 4,988,244 and 2,966,904 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively   5    3 
Additional paid-in capital   165,256    156,390 
Accumulated deficit   (138,203)   (124,303)
Total stockholders' equity   27,058    32,090 
Total liabilities and stockholders' equity  $44,803   $54,499 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 3 

 

 

ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except share and per share data)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2017   2016   2017   2016 
                 
Revenue, net of returns, allowances and discounts  $4,901   $4,375   $14,108   $11,851 
                     
Cost of revenues   1,538    1,608    4,765    4,493 
                     
Gross profit   3,363    2,767    9,343    7,358 
                     
Operating expenses                    
Selling, general and administrative   7,004    8,458    21,729    27,019 
Royalties   200    271    593    746 
Research and product development   1    164    121    692 
Milestone expense to licensor   -    1,000    -    1,000 
Acquisition-related   -    715    635    819 
Change in fair value of contingent consideration liability   -    97    35    (8,634)
Total operating expenses   7,205    10,705    23,113    21,642 
                     
Loss from operations   (3,842)   (7,938)   (13,770)   (14,284)
                     
Other (expense) income                    
Interest expense   (577)   (685)   (1,746)   (1,957)
Interest income   1    9    5    24 
Change in fair value of warrant liability   35    135    404    797 
Warrant modification expense   -    -    (803)   - 
Loss on early extinguishment of debt, net   (214)   (373)   (214)   (373)
Other income   67    100    67    100 
Total other expense   (688)   (814)   (2,287)   (1,409)
                     
Loss from continuing operations before tax   (4,530)   (8,752)   (16,057)   (15,693)
                     
Income tax expense   (3)   (3)   (9)   (9)
                     
Loss from continuing operations   (4,533)   (8,755)   (16,066)   (15,702)
                     
Discontinued operations:                    
Income from discontinued operations, net of tax of $0 for the three and nine months ended September 30, 2017 and 2016   133    167    466    1,293 
Gain on sale of assets, net of tax of $0 for the three and nine months ended September 30, 2017 and 2016   1,700    -    1,700    3,311 
Income from discontinued operations, net of tax   1,833    167    2,166    4,604 
                     
Net loss  $(2,700)  $(8,588)  $(13,900)  $(11,098)
                     
Net loss per basic and diluted common share:                    
Loss from continuing operations  $(0.95)  $(3.11)  $(3.89)  $(5.63)
                     
Income from discontinued operations   0.03    0.06    0.11    0.46 
Gain on sale of assets   0.36    -    0.41    1.19 
Total from discontinued operations   0.39    0.06    0.52    1.65 
Net loss per basic and diluted common share  $(0.56)  $(3.05)  $(3.37)  $(3.98)
                     
Weighted average shares used in computing net loss per basic and diluted common share   4,753,789    2,819,567    4,125,653    2,788,696 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 4 

 

 

ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

   Nine Months Ended September 30, 
   2017   2016 
Operating Activities           
Net loss  $(13,900)  $(11,098)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   4,111    3,124 
Amortization of deferred lease incentive    (34)   (23)
Deferred income tax expense   9    9 
Provision for doubtful accounts    169    37 
Reserve for note receivable   350    - 
Provision for excess and slow moving inventory    12    (54)
Stock-based compensation expense   1,604    4,268 
Deferred rent    2    84 
Accrued interest receivable   -    (3)
Amortization of debt issuance and discount costs    631    636 
Loss on early extinguishment of debt   182    321 
Warrant modification expense    803    - 
Change in fair value of warrant liability   (404)   (797)
Fair value adjustment of contingent consideration liability    35    (8,634)
Gain on sale of assets   (1,700)   (3,311)
Changes in operating assets and liabilities:           
Accounts receivable   (499)   (254)
Inventory    414    (643)
Prepaid expenses and other assets   439    55 
Accounts payable    (1,023)   (48)
Accrued expenses and other current liabilities   (1,000)   1,297 
Other long-term liabilities    -    1,000 
Net Cash Used in Operating Activities   (9,799)   (14,034)
           
Investing Activities          
Proceeds from sale of assets    3,412    4,103 
Purchase of improvements and equipment   (126)   (573)
Issuance of bridge loan    (350)   (500)
Net Cash Provided by Investing Activities   2,936    3,030 
           
Financing Activities          
Contingent purchase price payments    (675)   (2,573)
Repayment of long-term debt   (1,618)   (1,748)
Loss on early extinguishment of debt    (32)   (52)
Net proceeds from issuance of common stock   5,865    - 
Payment of withholding taxes related to stock-based employee compensation   (151)   (2)
Net Cash Provided by (Used in) Financing Activities   3,389    (4,375)
           
Net Decrease in Cash and Cash Equivalents   (3,474)   (15,379)
           
Cash and Cash Equivalents - Beginning of period   5,580    26,080 
           
Cash and Cash Equivalents - End of period  $2,106   $10,701 
           
Supplemental Disclosure of Cash Flows Information          
Cash paid during the period for:           
Interest  $1,008   $1,221 
Non-cash investing and financing activities:           
2016 Accrued bonus awarded in equity  $374   $- 
2015 Accrued bonus awarded in equity    -    474 
Common stock issued for contingent purchase price payments   1,175    2,574 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 5 

 

 

ALLIQUA BIOMEDICAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1.Description of Business and Basis of Presentation

 

Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue.

 

Basis of Presentation

 

The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2017 and results of operations and cash flows for the three and nine months ended September 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.

 

Reclassifications

 

Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.

 

Reverse Stock Split

 

The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

 

Discontinued Operations

 

In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective August 31, 2017, the Company entered into an Asset Purchase Agreement (“the Asset Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Asset Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $3.6 million for the TheraBond product line and certain other agreements between the parties and (ii) up to $112,000 for the unsold TheraBond inventory upon the Company’s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Asset Purchase Agreement. Of the $3.6 million of consideration, $300,000 is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company’s balance sheet as of September 30, 2017.

 

Additionally, effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH & Co KG.

 

The results of operations for the three and nine months ended September 30, 2017 and 2016 reflect the Company’s continuing operations.

 

 6 

 

 

Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2017   2016   2017   2016 
                 
Revenue, net of returns, allowances and discounts  $346   $499   $1,255   $3,155 
Cost of revenues   113    157    397    999 
Gross profit   233    342    858    2,156 
Selling, general and administrative   100    175    392    863 
Income from discontinued operations, net of tax  $133   $167   $466   $1,293 

 

Non-cash amortization expense of $43,000 and $74,000 is included in selling, general and administrative expense for the three months ended September 30, 2017 and 2016, respectively. Non-cash amortization expense of $185,000 and $260,000 is included in selling, general and administrative expense for the nine months ended September 30, 2017 and 2016, respectively.

 

During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $0) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):

 

Proceeds from sale          
Consideration for inventory  $112      
Consideration for intangible assets   3,600      
Total Consideration        3,712 
Less: Net book value of assets sold to Argentum          
Inventory, net   (303)     
Intangibles, net   (1,709)     
Total net book value of assets        (2,012)
Gain on sale of assets       $1,700 

 

During the nine months ended September 30, 2016, the Company recorded a gain of approximately $3.3 million (net of tax of $0) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):

 

Proceeds from sale          
Consideration for inventory  $603      
Consideration for intangible assets   3,500      
Total Consideration        4,103 
Less: Net book value of assets sold to BSN          
Inventory, net   (603)     
Intangibles, net   (189)     
Total net book value of assets        (792)
Gain on sale of assets       $3,311 

 

 7 

 

 

Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):

 

   September 30,   December 31, 
   2017   2016 
Accounts receivable, net  $164   $307 
Escrow   300    - 
Inventory, net   -    550 
Total current assets   464    857 
Intangible assets, net   -    1,893 
Total assets   464    2,750 
           
Accounts payable   19    19 
Accrued expenses and other current liabilities   18    41 
Total current liabilities  $37   $60 

 

On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (“Transition Agreement”). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum will pay the Company $200,000 for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. One-third of this compensation ($67,000) was recognized and is included in other income for the three and nine months ended September 30, 2017.

 

Significant Accounting Policies and Estimates

 

The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies in the 2016 Annual Report. Since the date of the 2016 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.  These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.

 

Recent Accounting Principles

 

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.

 

There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.

 

 8 

 

 

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.

 

2.Going Concern

 

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

As of September 30, 2017, the Company had a cash balance of approximately $2.1 million. The Company has experienced recurring losses since its inception. The Company incurred a net loss of $13.9 million and utilized $9.8 million in cash from operations for the nine months ended September 30, 2017, and had an accumulated deficit of $138.2 million as of September 30, 2017. As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement (as defined in Note 7- Debt) as a result of the Company’s failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017, respectively. Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.

 

On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive Credit Opportunities Fund, L.P. (“Perceptive”) entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”), pursuant to which the Company agreed to pay $1,650,000 of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.

 

Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company’s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to the Company’s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company’s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.

 

The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company’s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company’s assets after the expiration of the forbearance. Such action could hinder the Company’s ability to recover the remaining carrying value of some or all of its intangible assets including goodwill that aggregated approximately $35.2 million at September 30, 2017. These factors raise substantial doubt as to the Company’s ability to continue as a going concern within one year from the date of this filing. The ability of the Company to continue as a going concern is dependent upon the Company’s successful efforts to raise sufficient capital and attain profitable operations.

 

Management is evaluating all options to raise sufficient funds to meet its outstanding debt obligations and to fund the Company’s working capital requirements. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

 

 9 

 

 

3.Net Loss Per Common Share

 

Basic (loss) income per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted (loss) income per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock.

 

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

 

   Nine Months Ended Ended September 30, 
   2017   2016 
Options   879,182    733,862 
Warrants   514,561    336,541 
Non-vested restricted stock   194,674    147,322 
Total potentially dilutive shares   1,588,417    1,217,725 

 

4.Termination of Merger Agreement

 

On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, the Company terminated this agreement.

 

In connection with the merger agreement to acquire the business of Soluble, the Company provided Soluble with bridge loans in the form of subordinated promissory notes totaling approximately $1.4 million.  The Company advanced Soluble $1.0 million during the year ended December 31, 2016 and $350,000 on January 30, 2017.  Pursuant to the terms of the merger agreement, the amount was to be repaid in full upon termination of the agreement.  As of September 30, 2017, the Company fully reserved the amount due. As of December 31, 2016, the Company had provided for a full reserve for the amount that had been advanced to Soluble as of that date.  The Company recorded bad debt expense of $350,000 during the nine months ended September 30, 2017. This expense is included in acquisition related expense. The Company also incurred approximately $285,000 of other acquisition related expenses related to the Soluble transaction during the nine months period ended September 30, 2017. The net balance of the note receivable is $0 and is included in prepaid and other current assets as of September 30, 2017 and December 31, 2016.  See Note 12 - Subsequent Event.

 

5.Inventory

 

Inventory consists of the following (in thousands):

 

   September 30,   December 31, 
   2017   2016 
         
Raw materials  $115   $135 
Work in process   39    173 
Finished goods   1,843    1,845 
Less: Inventory reserve for excess and slow moving inventory   (12)   - 
Total  $1,985   $2,153 

 

 10 

 

 

6.Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consist of the following (in thousands):

 

   September 30,   December 31, 
   2017   2016 
         
Salaries, benefits and incentive compensation  $1,713   $3,007 
Milestone payment to licensor   1,000    1,000 
Professional fees   483    692 
Royalty fees   200    197 
Deferred revenue   339    181 
Other   141    147 
Total accrued expenses and other current liabilities  $3,876   $5,224 

 

7.Debt

 

Senior Secured Term Loan Facility

 

On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $15.5 million. The Credit Agreement (i) has a four-year term, (ii) accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%, (iii) is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date and (iv) is secured by a first priority lien on substantially all of the Company’s assets. The payment of principal under the Credit Agreement has been deferred until January 31, 2018, see Consent and Forbearance Agreement below. The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000. The interest rate at September 30, 2017 was 11.00%.

 

In connection with the Credit Agreement, the Company incurred approximately $1.3 million of debt issuance costs. The debt issuance costs are being amortized over the term of the loan on a straight-line basis, which approximates the effective interest method. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $61,000 and $64,000, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $190,000 and $209,000, respectively, which is included in interest expense.

 

In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 75,000 shares of common stock, par value of $0.001 per share at an exercise price of $55.138 per share (the “Exercise Price”) was issued to Perceptive. The Company granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. The Warrant contains a weighted average anti-dilution feature whereby the Exercise Price is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current Exercise Price. As a result, the Warrant was determined to be a derivative liability. The Warrant had an issuance date fair value of approximately $2.7 million which was recorded as a debt discount. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $144,000 and $143,000, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $441,000 and $427,000, respectively, which is included in interest expense for the periods presented. See Note 11 – Fair Value Measurement for additional details.

 

As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company’s failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017, respectively. The Company has classified the entire principal balance as a current liability in its balance sheet as of September 30, 2017 and December 31, 2016.

 

The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70. The amended and restated Warrant, as amended, contains a weighted average anti-dilution feature whereby the exercise price of the amended and restated warrant is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current exercise price of such warrant. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. See Note 11 – Fair Value Measurement for additional details.

 

 11 

 

 

Debt consists of the following (in thousands):

 

   September 30,   December 31, 
   2017   2016 
         
Principle balance  $12,135   $13,752 
Unamortized debt issuance and discount costs   (1,399)   (2,211)
Total  $10,736   $11,541 

 

Consent and Forbearance Agreement

 

Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.

 

On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”), pursuant to which the Company agreed to pay $1,650,000 of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.

 

Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company’s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to the Company’s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company’s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.

 

The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company’s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company’s assets after the expiration of the forbearance.

 

8.Commitments and Contingencies

 

Agreements for Human Placental Based Products

 

Human Longevity, Inc.

 

In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The agreements grant the Company an exclusive, royalty-bearing license in CCT’s intellectual property for certain placental based products, including ECM and Biovance ®, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, HLI Cellular Therapeutics, LLC (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. In June 2017, Celularity, Inc. (“Celularity”) acquired all of the assets of HLI, including the agreements between HLI and the Company. The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. For the three months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $199,000 and $121,000, respectively, in connection with this agreement. For the nine months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $591,000 and $296,000, respectively, in connection with this agreement. Approximately $199,000 and $197,000 is included in accrued expenses as of September 30, 2017 and December 31, 2016, respectively, in connection with this agreement. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term.

 

 12 

 

 

The License Agreement with Celularity is terminable on a product-by-product basis if the Company fails to meet certain minimum sales thresholds in the second year or any subsequent year of commercial sales of each licensed product. Each year of commercial sales are referred to in the License Agreement as “launch years” and the calendar period constituting each launch year for each licensed product is determined in accordance with the terms of the License Agreement. To maintain its license for Biovance, the Company must meet a minimum gross sales amount for Biovance in the second year and third year of commercial sales. If the Company fails to meet the minimum threshold in the second year of commercial sales of product, it would be able to cure such failure by making a cure payment specified in the License Agreement to Celularity; provided, however, the Company does not have the option to make a cure payment, should it fail to meet the minimum threshold for such product in the third year of commercial sales and Celularity may terminate the License Agreement with respect to such product.

 

In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product, also known as Interfyl.

 

In April 2016, the Company entered into a Supply Agreement with HLI (now Celularity), pursuant to which Celularity supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay Celularity $500,000 related to the first commercial sale of Interfyl in the flowable matrix configuration and $500,000 related to the first commercial sale of Interfyl in the particulate form. Commercial sales of both configurations occurred in September 2016, and as such, the Company recorded $1.0 million of milestone expense during the year ended December 31, 2016. The milestone has been included in accrued expenses and other current liabilities as of September 30, 2017 and December 31, 2016.

 

Contingent Consideration

 

Celleration, Inc.

 

On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. The Company agreed to pay contingent consideration of 3.5 times revenue from acquired MIST Therapy products in excess of certain revenue targets for the years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Company’s common stock. This contingent consideration was payable in two installments in March 2016 and March 2017.

 

The first installment consisted of $2.6 million of cash and approximately 98,600 shares of the Company’s common stock valued at approximately $2.6 million and was paid in March 2016. This payment was based on 3.5 times of the excess of 2015 MIST Therapy revenue of approximately $10.2 million over 2014 MIST Therapy revenue of approximately $8.7 million.

 

The second installment consisted of $675,000 of cash and approximately 100,000 shares of the Company’s common stock valued at approximately $675,000 and was paid in March 2017. This payment was based on 3.5 times of the excess of 2016 MIST Therapy revenue of approximately $10.5 million over 2015 MIST Therapy revenue of approximately $10.2 million. There are no further contingent payments due in connection with the Celleration acquisition.

 

Choice Therapeutics, Inc.

 

On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company agreed to pay contingent consideration based upon the Company achieving specific performance metrics over the three twelve-month periods, ended April 30, 2017. The Company issued approximately 130,000 shares of its common stock valued at approximately $500,000 in June 2017. There are no further contingent payments due in connection with the Choice acquisition.

 

Litigation, Claims and Assessments

 

The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2017.

 

 13 

 

 

9.Stockholders’ Equity

 

Private Placement

 

On February 27, 2017, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “Private Placement”) an aggregate of 554,000 shares of the Company’s common stock at a purchase price of $5.00 per share. The Company closed the Private Placement on the same day as it entered into the Securities Purchase Agreement and received aggregate gross proceeds of approximately $2.8 million. In connection with the Private Placement, the Company paid an aggregate of $196,000 of financial advisory fees and $40,000 of administrative fees, which were recorded as a reduction of additional paid-in capital.

 

The Securities Purchase Agreement contains a “most-favored nation” provision that provides that if the Company, during 120 days from February 27, 2017, issues or sells any common stock or common stock equivalents reasonably believed to be more favorable in terms or conditions than those in the Private Placement, then the Company must amend the terms of the Securities Purchase Agreement to give the private investors the benefit of such favorable terms or conditions. In connection with the common stock sold in the Public Offering (as defined below) and in accordance with this provision, on April 11, 2017, the Company issued an aggregate of 38,072 shares of its common stock to these investors. On June 23, 2017, the Company held its 2017 annual meeting of stockholders during which the stockholders approved the issuance of the remaining 100,429 additional shares of common stock to be issued to the investors, and, following the meeting, on June 23, 2017, the Company issued the remaining shares.

 

Underwritten Public Offering

 

On April 3, 2017, the Company closed an underwritten public offering (the “Public Offering”) of 947,325 shares of its common stock at a price to the public of $4.00 per share. The Company received aggregate gross proceeds of approximately $3.8 million. In connection with the Public Offering, the Company paid an aggregate of $365,000 of financial advisory fees and $92,000 of administrative fees, which were recorded as a reduction of additional paid-in capital. The shares of common stock were issued pursuant to the Company’s shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September 25, 2014.

 

On April 3, 2017, the Company issued warrants to purchase an aggregate of 23,684 shares of the Company’s common stock to the underwriter of this offering. These warrants are immediately exercisable, have an exercise price of $4.40, and expire on March 29, 2022. The warrants had an aggregate issuance date fair value of $78,000 which was recorded as both a debit and credit to additional paid in capital.

 

Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $21.90, the exercise price of these warrants was adjusted to the public offering price of $4.00. As of April 3, 2017, November 2012 warrants to purchase 36,230 shares of the Company’s common stock were outstanding. These warrants expire in November 2017.

 

Stock-Based Compensation

 

For the three months ended September 30, 2017 and 2016, the Company recognized $686,000 and $1.2 million of stock-based compensation expense, of which, ($1,000) and $5,000 is included in cost of revenues and $687,000 and $1.2 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. For the nine months ended September 30, 2017 and 2016, the Company recognized $1.6 million and $4.3 million of stock-based compensation expense, of which, $25,000 and $134,000 is included in cost of revenues and $1.6 million and $4.1 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. As of September 30, 2017, there was $1.4 million of unrecognized stock-based compensation expense which will be amortized over a weighted average period of 0.8 years.

 

Stock Options

 

On June 27, 2017, the Company granted non-executive employees ten-year options to purchase an aggregate of 208,050 shares of common stock at an exercise price of $3.50 per share. The aggregate grant date value of the options is $519,000. The options vest in one-fourth increments every six months over a period of two years.

 

Restricted Stock

 

During the nine months ended September 30, 2017, the Company granted an aggregate of 181,936 shares of restricted stock to employees with an aggregate grant date value of $621,000 which will be recognized proportionate to the vesting period. The shares vest as follows: (i) 66,936 shares vested on September 21, 2017, (ii) 5,000 shares vest on December 31, 2017, (iii) 50,000 shares vest on June 23, 2018, and (iv) 60,000 shares vest pursuant to the satisfaction of certain performance conditions.

 

 14 

 

 

10.Related Party

 

In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then a member of the Board of Directors. During the three months ended September 30, 2017 and 2016, the Company incurred costs of approximately $28,000 and $100,000, respectively, from this vendor. During the nine months ended September 30, 2017 and 2016, the Company incurred costs of approximately $286,000 and $358,000, respectively, from this vendor. Approximately $39,000 and $102,000 is included in accounts payable related to this related party as of September 30, 2017 and December 31, 2016, respectively.

 

11.Fair Value Measurement

 

Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:

 

Level 1: Observable prices in active markets for identical assets and liabilities.

 

Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.

 

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

 

Warrant Liabilities

 

The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70 per share. See Note 7 – Debt for additional details. In connection with the amendments of January, March, April and June 2017, the Company recomputed the fair value of the original warrant and amended warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 65.33%-78.98%, risk-free rate of 1.49%-1.95%, expected term of 3.34-5.00 years, and expected dividends of 0.00%. As a result, the Company recorded warrant modification expense of $0 and $803,000 during the three and nine months ended September 30, 2017, respectively, which represents the incremental value of the amended warrant as compared to the original warrant, both valued as of the respective amendment dates.

 

On September 30, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 246,231 shares of common stock as $419,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 72.63%-131.85%, risk-free rate of 0.96%-1.77%, expected term of 0.10-4.32 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $35,000 and $404,000 during the three and nine months ended September 30, 2017, respectively.

 

The issuance of common stock in connection with the Private Placement and Public Offering triggered an adjustment to the exercise price of certain warrants originally issued in November 2012 from $55.10 per share to $5.00 per share to $4.00 per share with a corresponding adjustment to the number of shares underlying such warrants from 6,629 shares to 29,034 shares to 36,231 shares. The impact of such adjustment is included in the change in fair value of the warrant liabilities during the nine months ended September 30, 2017.

 

Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

 

 15 

 

 

The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands):

 

   Nine Months Ended September 30, 
   2017   2016 
Warrant Liabilities          
Beginning balance  $20   $861 
Change in fair value of warrant liability   (404)   (797)
Warrant modification expense   803    - 
Ending balance  $419   $64 

 

   Nine Months Ended September 30, 
   2017   2016 
Contingent Consideration          
Beginning balance  $1,816   $17,028 
Payments of contingent consideration   (1,851)   (5,147)
Change in fair value of contingent consideration   35    (8,634)
Ending balance  $-   $3,247 

 

Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):

 

   September 30, 2017 
   Level 1   Level 2   Level 3 
Liabilities:               
Warrant liabilities  $-   $-   $419 
Total liabilities  $-   $-   $419 

 

   December 31, 2016 
   Level 1   Level 2   Level 3 
Liabilities:               
Warrant liabilities  $-   $-   $20 
Contingent consideration   -    -    1,816 
Total liabilities  $-   $-   $1,836 

 

12.Subsequent Event

 

The Company advanced Soluble $1.4 million, $1.0 million during the year ended December 31, 2016 and $350,000 on January 30, 2017. 

 

On October 27, 2017, the Company received $1 million under an agreement with Soluble in connection with amounts advanced to Soluble by the Company. With the receipt of this $1 million, the Company acknowledged that all amounts due to the Company from Soluble are paid in full.

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes above.

 

 16 

 

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will actually be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

·our ability to continue as a going concern;

 

  · inadequate capital;

 

  · the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;

 

  · our ability to recover the carrying value of some or all of our intangible assets including goodwill;

 

  · our ability to obtain reimbursement from third party payers for our products;
     
  · our ability to achieve and maintain minimum sales requirements under our license agreements;

 

  · our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop;

 

  · our ability to cure or obtain forbearance or waivers for existing covenant defaults under our outstanding indebtedness and to remain in compliance with our debt covenants;

 

  · market acceptance of our existing and future products;

 

  · loss or retirement of key executives;

 

  · our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so;

 

  · an unfavorable decision on product reimbursement;

 

  · adverse economic conditions and/or intense competition;

 

  · loss of a key customer or supplier;

 

  · entry of new competitors and products;

 

  · adverse federal, state and local government regulation;

 

  · technological obsolescence of our products;

 

  · technical problems with our research and products;

 

  · risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings;

 

  · price increases for supplies and components; and

 

  · the inability to carry out research, development and commercialization plans.

 

For a discussion of these and other risks that relate to our business and investing in shares of our common stock, you should carefully review the risks and uncertainties described under the heading “Part II – Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on form 10-K for the year ended December 31, 2016. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

 

 17 

 

 

Overview

 

We are a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Through our sales and distribution network, together with our proprietary products, we believe we offer solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Our contract manufacturing business provides custom hydrogels to the OEM market.

 

Recent Events

 

Termination of Merger Agreement

 

On October 5, 2016, we entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, we terminated this agreement.

 

We advanced Soluble $1.4 million, $1.0 million during the year ended December 31, 2016 and $350,000 on January 30, 2017.

 

On October 27, 2017, we received $1 million under an agreement with Soluble in connection with amounts advanced to Soluble by us. With the receipt of this $1 million, we acknowledged that all amounts due to us from Soluble are paid in full.

 

Private Placement

 

On February 27, 2017, we issued and sold an aggregate of 554,000 shares of our common stock at a purchase price of $5.00 per share issued to certain accredited investors in a private placement (the “Private Placement”), pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”). Proceeds from the Private Placement, net of underwriting and administrative fees, were approximately $2.5 million.

 

Underwritten Public Offering

 

On April 3, 2017, we closed an underwritten public offering of 947,325 shares of our common stock at a price to the public of $4.00 per share. Proceeds from this offering, net of underwriting and administrative fees were approximately $3.3 million. The shares of common stock were issued pursuant to our shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September 25, 2014.

 

On April 3, 2017, we issued warrants to purchase an aggregate of 23,684 shares of our common stock to the underwriter of this offering. These warrants are immediately exercisable, have an exercise price of $4.40, and expire on March 29, 2022.

 

Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $21.90, the exercise price of these November 2012 warrants was adjusted to the public offering price of $4.00. As of April 3, 2017, November 2012 warrants to purchase 36,230 shares of the Company’s common stock were outstanding. These warrants expire in November 2017.

 

Amendment and Adjustments of the Perceptive Warrant

 

On April 6, 2017, we and Perceptive Credit Opportunities Fund, L.P. (“Perceptive”) entered into an amendment and restatement of a warrant to reduce the exercise price from $5.00 to $4.70, reflecting the impact of the public offering price of $4.00 per share at which we sold our common stock in the underwritten public offering that closed on April 3, 2017 as described above. The warrant was exercisable for 200,000 shares of our common stock. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. On June 1, 2017, we and Perceptive entered into an amendment to increase the warrant from 200,000 to 210,000 shares of our common stock as well as delay the principal payments due under the Credit Agreement beginning June 30, 2017 until August 31, 2017.

 

Senior Secured Term Loan Facility

 

As of September 30, 2017, we are in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of our failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017, respectively. Under an agreement dated January 26, 2017, as amended on March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.

 

 18 

 

 

On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, we entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”) with Perceptive, pursuant to which we agreed to pay $1,650,000 of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, we recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.

 

Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of our remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to our default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to our default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.

 

The lender has the rights to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of our assets and, as a result of the default, may seek to foreclose on some or substantially all of our assets after the expiration of the forbearance. We are in negotiations with other financing parties to refinance this debt. However, no assurance can be given that we will be able to obtain additional debt to refinance our existing obligations on commercially reasonable terms or at all.

 

Asset Sale

 

In order to add capital and to focus on future investments on commercializing our own regenerative technologies effective August 31, 2017, we entered into a purchase agreement with Argentum Medical, LLC. (“Argentum”) whereby we agreed to sell to Argentum all of our rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased in existence as of the closing, which occurred upon execution and delivery of the Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum, Argentum agreed to pay (i) $3.6 million for the TheraBond product line and certain other agreements between the parties and (ii) up to $112,000 for to the unsold TheraBond inventory upon our completion of our obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the purchase agreement. Of the $3.6 million of consideration, $300,000 is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on our balance sheet as of September 30, 2017.

 

Reverse Stock Split

 

On October 5, 2017, we effected a 1-for-10 reverse stock split of our outstanding common stock. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

 

Results of Operations

 

Three Months Ended September 30, 2017 Compared to the Three Months Ended September 30, 2016

 

Revenues, net. For the three months ended September 30, 2017 revenues increased by $526,000, or 12%, to $4.9 million from $4.4 million for the three months ended September 30, 2016.   The increase in our overall revenue was due to a 14% increase in product sales, primarily attributable to growth in our biologic products. During the third quarter, the hurricanes in Texas and Florida had a negative impact on sales of our biologics products.

 

 19 

 

 

The components of revenue were as follows for the three months ended September 30, 2017 and 2016 (in thousands):

  

   Three Months Ended September 30, 
   2017   2016 
Revenues          
Product  $4,406   $3,856 
Contract manufacturing   495    519 
Total revenues, net  $4,901   $4,375 

 

Gross profit. Our gross profit was $3.4 million for the three months ended September 30, 2017 compared to gross profit of $2.8 million for the three months ended September 30, 2016.  The improved results for the three months ended September 30, 2017, as compared to the three months ended September 30, 2016 was primarily due to the greater volume of product sales as product revenue typically commands higher gross profit margins. Gross margin on our product sales was approximately 77%, while our overall gross margin was approximately 69% for the three months ended September 30, 2017. Gross margin on our product sales was approximately 76%, while our overall gross margin was approximately 63% for the three months ended September 30, 2016.

 

The components of cost of revenues are as follows for the three months ended September 30, 2017 and 2016 (in thousands):

 

   Three Months Ended September 30, 
   2017   2016 
Cost of revenues          
Materials and finished products  $961   $940 
Stock-based compensation   (1)   5 
Compensation and benefits   135    220 
Depreciation and amortization   211    201 
Equipment, production and other expenses   232    242 
Total cost of revenues  $1,538   $1,608 

 

Selling, general and administrative expenses. The following table highlights selling, general and administrative expenses by type for the three months ended September 30, 2017 and 2016 (in thousands):

 

   Three Months Ended September 30, 
   2017   2016 
Selling, general and administrative expenses          
Compensation and benefits  $2,974   $3,746 
Stock-based compensation   687    1,184 
Professional fees   638    880 
Marketing   371    520 
Depreciation and amortization   1,101    764 
Other expenses   1,233    1,364 
Total selling, general and administrative expenses  $7,004   $8,458 

 

Selling, general and administrative expenses decreased by $1.5 million to $7.0 million for the three months ended September 30, 2017, as compared to $8.5 million for the three months ended September 30, 2016. The decrease in selling, general and administrative expenses is consistent with our goal of decreasing our operating expenditures.

 

Compensation and benefits decreased by $772,000 to $3.0 million for the three months ended September 30, 2017, as compared to $3.7 million for the three months ended September 30, 2016. The decrease in compensation and benefits was primarily due to the decrease in the average number of full-time employees in 2017 compared to 2016, offset by an increase in sales based commission due to the increase in product revenue. We expect our average headcount for the full year of 2017 to be lower than the full year of 2016.

 

Stock-based compensation decreased by $497,000, to $687,000 for the three months ended September 30, 2017, as compared to $1.2 million for the three months ended September 30, 2016.  The decrease in stock-based compensation is primarily due to the lower weighted average estimated fair value of options vested during the three months ended September 30, 2017 as compared to the three months ended September 30, 2016.

 

 20 

 

 

Nine Months Ended September 30, 2017 Compared to the Nine Months Ended September 30, 2016

 

Revenues, net. For the nine months ended September 30, 2017 revenues increased by $2.3 million, or 19%, to $14.1 million from $11.9 million for the nine months ended September 30, 2016.   The increase in our overall revenue was due to a 28% increase in product sales, primarily attributable to growth in our biologic products.

 

The components of revenue were as follows for the nine months ended September 30, 2017 and 2016 (in thousands):

 

   Nine Months Ended September 30, 
   2017   2016 
Revenues          
Product  $12,778   $9,970 
Contract manufacturing   1,330    1,881 
Total revenues, net  $14,108   $11,851 

 

Gross profit. Our gross profit was $9.3 million for the nine months ended September 30, 2017 compared to gross profit of $7.4 million for the nine months ended September 30, 2016.  The improved results for the nine months ended September 30, 2017, as compared to the nine months ended September 30, 2016 was primarily due to the greater volume of product sales as product revenue typically commands higher gross profit margins. Gross margin on our product sales was approximately 76%, while our overall gross margin was approximately 66% for the nine months ended September 30, 2017. Gross margin on our product sales was approximately 77%, while our overall gross margin was approximately 62% for the nine months ended September 30, 2016.

 

The components of cost of revenues are as follows for the nine months ended September 30, 2017 and 2016 (in thousands):

 

   Nine Months Ended September 30, 
   2017   2016 
Cost of revenues          
Materials and finished products  $2,903   $2,425 
Stock-based compensation   25    134 
Compensation and benefits   550    723 
Depreciation and amortization   626    574 
Equipment, production and other expenses   661    637 
Total cost of revenues  $4,765   $4,493 

 

Selling, general and administrative expenses. The following table highlights selling, general and administrative expenses by type for the nine months ended September 30, 2017 and 2016 (in thousands):

 

   Nine Months Ended September 30, 
   2017   2016 
Selling, general and administrative expenses          
Compensation and benefits  $9,883   $11,513 
Stock-based compensation   1,579    4,142 
Professional fees   2,099    2,820 
Marketing   1,205    1,616 
Depreciation and amortization   3,305    2,290 
Other expenses   3,658    4,638 
Total selling, general and administrative expenses  $21,729   $27,019 

 

Selling, general and administrative expenses decreased by $5.3 million to $21.7 million for the nine months ended September 30, 2017, as compared to $27.0 million for the nine months ended September 30, 2016. The decrease in selling, general and administrative expenses is consistent with our goal of decreasing our operating expenditures.

 

Compensation and benefits decreased by $1.6 million to $9.9 million for the nine months ended September 30, 2017, as compared to $11.5 million for the nine months ended September 30, 2016. The decrease in compensation and benefits was primarily due to the decrease in the average number of full-time employees in 2017 compared to 2016, offset by an increase in sales based commission due to the increase in product revenue. We expect our average headcount for the full year of 2017 to be lower than the full year of 2016.

 

 21 

 

 

Stock-based compensation decreased by $2.5 million, to $1.6 million for the nine months ended September 30, 2017, as compared to $4.1 million for the nine months ended September 30, 2016.  The decrease in stock-based compensation is primarily due to the lower weighted average estimated fair value of options vested during the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016.

 

Professional fees decreased by $721,000 to $2.1 million for the nine months ended September 30, 2017, as compared to $2.8 million for the nine months ended September 30, 2016. The decrease in professional fees was primarily due to a decrease in legal and consulting expenses offset by an increase in commissions paid to independent sales representatives.

 

Other expenses decreased by $981,000 to $3.7 million for the nine months ended September 30, 2017 from $4.6 million for the nine months ended September 30, 2016. Other selling, general and administrative expenses consist of costs associated with our selling efforts and general management, including information technology, travel, training and recruiting. The decrease in other expenses is primarily due to a decrease in the average number of full-time employees in the nine months ended September 30, 2017 compared to the same period in 2016, as well as our goal of decreasing operating expenses.

 

Acquisition-related expenses. During the nine months ended September 30, 2017, we incurred $635,000 in acquisition-related costs related to acquisition of Soluble, which we terminated in February 2017. The incurred costs during the nine months ended September 30, 2017 include bad debt expense of $350,000 related to a subordinated promissory note receivable made to Soluble in connection with the terminated acquisition, as well as professional costs associated with terminating the acquisition. Subsequent to September 30, 2017, we received $1,000,000 in connection with the subordinated promissory note receivable.

 

Warrant modification expense. During the nine months ended September 30, 2017, we recognized $803,000 of warrant modification expense in connection with the amendment of the warrant issued to Perceptive. In connection with entry into the January 2017 forbearance agreement, as amended March and June 2017, we also amended and restated the warrant issued to Perceptive in connection with the closing of the Credit Agreement in May 2015. The amended and restated warrant is exercisable for 210,000 shares of our common stock. The expense recorded during the nine months ended September 30, 2017 represents the incremental value of the modified warrant as compared to the original warrant, both valued as of the respective modification dates.

 

Liquidity and Capital Resources

 

As of September 30, 2017, we had cash and cash equivalents totaling approximately $2.1 million compared to $5.6 million at December 31, 2016.  The decrease was largely attributable to cash used in operating activities of approximately $9.8 million, $1.6 million paid to Perceptive for the early extinguishment of debt, $675,000 to pay a portion of the contingent consideration related to the Celleration acquisition, and $350,000 issued as a bridge loan to Soluble in connection with the terminated acquisition. This decrease was offset by $5.9 million received from net proceeds from the issuance of common stock and the proceeds of $3.4 million from the sale of TheraBond.

 

Net cash used in operating activities was $9.8 million and $14.0 million for the nine months ended September 30, 2017 and 2016, respectively. Net cash used in operating activities for both periods was principally to fund our net cash loss. The net cash flow used in operating activities for the nine months ended September 30, 2017 and 2016 included $1.6 million of compensation and royalty payments that were accrued at December 31, 2016 and 2015, respectively. The nine months ended September 30, 2017 also includes $711,000 of payments in connection with the terminated acquisition of Soluble.

 

Net cash provided by investing activities was $2.9 million and $3.0 million for the nine months ended September 30, 2017 and 2016, respectively. Cash provided by investing activities during the nine months ended September 30, 2017 included $3.4 million received from the sale of the rights to the TheraBond product from Argentum, offset by $350,000 provided to Soluble as a bridge loan and $126,000 in purchases of improvements and equipment. Cash provided by investing activities during the nine months ended September 30, 2016 included $4.1 million received from the sale of the rights to the sorbion product from BSN, offset by purchases of improvements and equipment of $573,000 and $500,000 provided to Soluble as a bridge loan.

 

Net cash provided by financing activities for the nine months ended September 30, 2017 consisted of $5.9 million of net proceeds received from the issuance of our common stock offset by $675,000 utilized to pay the cash portion of the contingent consideration related to the Celleration acquisition and the early extinguishment of debt of $1.6 million. Net cash used in financing activities for the nine months ended September 30, 2016 consisted of $2.6 million utilized to pay the cash portion of the contingent consideration related to the Celleration acquisition and the early extinguishment of debt of $1.7 million.

 

At September 30, 2017, current assets totaled $7.8 million and current liabilities totaled $16.7 million, as compared to current assets totaling $11.8 million and current liabilities totaling $20.1 million at December 31, 2016. As a result, we had negative working capital of $8.9 million at September 30, 2017 compared to negative working capital of $8.3 million at December 31, 2016.

 

 22 

 

 

Our cash requirements have historically been needed for mergers and acquisitions, post-market clinical trials, marketing and sales activities, finance and administrative costs, capital expenditures and overall working capital. We have experienced negative operating cash flows since inception and have funded our operations primarily from sales of common stock and other securities.

 

Liquidity Outlook

 

Our financial statements have been prepared assuming we will continue as a going concern. We have experienced recurring losses since our inception. We incurred a net loss of $13.9 million and used $9.8 million in cash from operations for the nine months ended September 30, 2017, and had an accumulated deficit of $138.2 million as of September 30, 2017. At September 30, 2017, we had approximately $2.1 million of cash and cash equivalents.

 

On October 27, 2017, we received $1,000,000 as repayment of amounts advanced to Soluble in 2016 and 2017.

 

We are currently in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of our failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017 respectively. Under an agreement dated January 26, 2017, as amended on March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.

 

On August 31, 2017 we entered in a Consent, Forbearance and Amendment Agreement with the lender. Under this agreement, the lender agreed to: (a) release its liens on the TheraBond assets purchased by Argentum; (b) defer the commencement of our principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to our default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default.

 

On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.

 

The lender has the rights to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of our assets and, as a result of the default, may seek to foreclose on some or substantially all of our assets after the expiration of the forbearance. We are in discussions with our lender to refinance this debt. However, no assurance can be given that we will be able to refinance our existing obligations on commercially reasonable terms or at all.

  

Even though we have taken steps to reduce our operating expenditures, we expect to continue incurring losses and negative cash flows from operations until our products reach commercial profitability. Our cash used from operating activities for the three months ended September 30, 2017 was approximately $1.8 million. We do not expect our cash used in operations to change significantly over the next several fiscal quarters. We, therefore, believe we do not have sufficient resources to fund operations beyond the first fiscal quarter of 2018 and we will need to raise additional capital to finance our losses and negative cash flows from operations. In addition, the lender may declare due and payable our current outstanding principal balance of $12.1 million in full following the termination of a forbearance agreement.

 

Therefore, due to our history of recurring losses and our negative working capital, there is substantial doubt about our ability to continue operating as a going concern within one year from the date of this filing. Our plans include the continued commercialization of our products, raising capital through the sale of additional equity and/or debt securities, and exploring other strategic alternatives. There can be no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in raising additional capital, we may need to reduce activities, curtail or cease operations.

 

 23 

 

 

Off Balance Sheet Arrangements

 

As of September 30, 2017, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to unconsolidated entities (or similar arrangements serving as credit, liquidity or market risk support to unconsolidated entities for any such assets), or obligations (including contingent obligations) arising out of variable interests in unconsolidated entities providing financing, liquidity, market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.

 

Critical Accounting Policies

 

There have been no significant changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the Annual Report on Form 10-K for the year ended December 31, 2016.

 

Recent Accounting Pronouncements

 

Recently issued accounting pronouncements are addressed in Note 1 in the Notes to Condensed Consolidated Financial Statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures.

 

As of September 30, 2017, we conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls were effective at the reasonable assurance level as of September 30, 2017.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II OTHER INFORMATION

 

ITEM 1.  LEGAL PROCEEDINGS

 

From time to time, we may become involved in lawsuits, investigations and claims that arise in the ordinary course of business. As of the date of this filing, we are not party to any material litigation nor are we aware of any such threatened or pending legal proceedings that we believe could have a material adverse effect on our business, financial condition or operating results.

 

There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

 

 24 

 

 

ITEM 1A.  RISK FACTORS

 

During the three months ended September 30, 2017, there were no material changes to the risk factors previously discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the quarter ended March 31, 2017 and June 30, 2017, except for the following:

 

We are currently in default under the Credit Agreement, which allows the lender to exercise certain rights and remedies, including, without limitation, declaring the entire outstanding indebtedness under the Credit Agreement of approximately $12.1 million immediately due and payable, imposing a default rate of interest and/or foreclosing on some or substantially all of our assets.

 

We are currently in default of the Credit Agreement, as a result of our failure to achieve $24,600,000, $27,000,000, $30,300,000 and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017, respectively. Under an agreement dated November 7, 2017, Perceptive Credit Opportunities Fund, L.P., the lender, agreed to forbear from exercising any rights and remedies related to the default until the earlier of December 31, 2017, or the date when the lender becomes aware of any other default. The remedies available for the lender include, among others, the ability to accelerate and immediately demand payment of the outstanding debt of approximately $12.1 million under the Credit Agreement, to impose a default rate of interest, to foreclose on some or all of our assets, and/or to take possession of or sell some or all of our assets. Were the lender to demand payment of the outstanding debt after expiration of the forbearance period, we would currently have insufficient funds to satisfy that obligation, and the lender’s exercise of its other remedies would have a material adverse effect on our operations and financial condition.

 

We are exploring initiatives to address solutions to our credit issues, which include a restructuring of the Credit Agreement with the lender and the evaluation and pursuit of various sources of financing including a refinancing. However, no assurance can be given that we can restructure our Credit Agreement or that additional financing will be available on commercially reasonable terms or at all.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

(a)Unregistered Sales of Equity Securities

 

None

 

(b)Issuer Purchases of Equity Securities

 

The following table sets forth information with respect to purchases by us of our equity securities during the three months ended September 30, 2017:

 

Issuer's Purchases of Equity Securities
                 
Period  Total number of
shares (or units)
purchased		   Average price paid
per share (or unit)(1)		   Total number of
shares (or units)
purchased
as part of publicly
announced plans or
programs		   Maximum number (or
approximate dollar value) of
shares (or units) that may
yet be purchased under the
plans or programs		 
7/1/2017 to 7/31/2017   -   $-    -    - 
8/1/2017 to 8/31/2017   -         -    - 
9/1/2017 to 9/30/2017   22,296(2)   4.20    -    - 
Total   22,296   $4.20    -    - 

 

(1) For purposes of determining the number of shares to be surrendered to meet tax withholding obligations, the price per share deemed to be paid was the closing price of our common stock on the NASDAQ Capital Market on the applicable vesting date.

 

(2) Includes 22,296 shares of our common stock surrendered by employees to pay tax withholding obligations incurred in connection with the vesting of restricted stock on September 21, 2017.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 25 

 

 

ITEM 5. OTHER INFORMATION

 

Not applicable.

 

ITEM 6. EXHIBITS

 

See “Index to Exhibits” for a description of our exhibits.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ALLIQUA BIOMEDICAL, INC.
     
Date: November 9, 2017 By: /s/ David Johnson
  Name: David Johnson
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
  By: /s/ Brian M. Posner
  Name: Brian M. Posner
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

 26 

 

 

Index to Exhibits

 

Exhibit No.   Description
     
3.1   Certificate of Incorporation of Alliqua BioMedical, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 11, 2014).
3.2   Bylaws of Alliqua BioMedical, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on June 11, 2014).
3.3   Certificate of Amendment to Certificate of Incorporation of Alliqua BioMedical, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed on June 11, 2014).
3.4   Certificate of Amendment to Certificate of Incorporation of Alliqua BioMedical, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 6, 2016).
3.5   Certificate of Amendment of Certificate of Incorporation of Alliqua BioMedical, Inc. dated October 5, 2017 (incorporated by reference in Exhibit 3.1 to the Current Report on Form 8-K filed on October 5, 2017).
4.1   Form of Underwriter Warrant, dated April 3, 2017, incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2017.
10.1   Second Forbearance Agreement, dated August 9, 2017, by and among Alliqua BioMedical, Inc., Aquamed Technologies, Inc. and Perceptive Credit Opportunities Fund, LP (incorporated by reference to the Current Report on Form 8-K filed on August 10, 2017).
10.2   Asset Purchase Agreement, dated August 31, 2017, by and between Alliqua BioMedical, Inc. and Argentum Medical, LLP (incorporated by reference to the Current Report on Form 8-K filed on September 5, 2017).
10.3   Consent, Forbearance and Amendment Agreement, dated August 31, 2017, by and among Alliqua BioMedical, Inc. and Perceptive Credit Opportunities Fund, LP (incorporated by reference to the Current Report on Form 8-K filed on September 5, 2017).
10.4*   Third Forbearance Agreement, dated November 7, 2017, by and between Alliqua BioMedical, Inc., Aquamed Technologies, Inc. and Perceptive Credit Holdings, L.P.
31.1*   Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
31.2*   Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
32.1*   Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*   The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders’ Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.

 

* Filed herewith.

 

 27 

 

 EX-10.4 2 tv478458_ex10-4.htm EXHIBIT 10.4

Exhibit 10.4

 

Execution Copy

 

THIRD FORBEARANCE AGREEMENT

 

This THIRD FORBEARANCE AGREEMENT, dated as of November 7, 2017 (this “Agreement”), is made by and among ALLIQUA BIOMEDICAL, INC., a Delaware Corporation (the “Borrower”), AQUAMED TECHNOLOGIES, INC., a Delaware corporation (the “Guarantor”; the Borrower and the Guarantor are each also referred to herein individually as a “Loan Party” and collectively as the “Loan Parties”) and PERCEPTIVE CREDIT HOLDINGS, L.P., a Delaware limited partnership (the “Lender”). Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement (defined below).

 

W I T N E S S E T H:

 

WHEREAS, the Borrower, the Guarantor and the Lender are parties to that certain Credit Agreement and Guaranty, dated as of May 29, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”);

 

WHEREAS, pursuant to Sections 8.4(a) and (b) of the Credit Agreement, (a) the Loan Parties are required to maintain, on a consolidated basis, a monthly minimum balance of $2,000,000 in unrestricted, unencumbered cash in one or more Controlled Accounts that are free and clear of all Liens, subject to certain exceptions, (b) Consolidated Total Revenue of the Borrower for the twelve consecutive month period ended September 30, 2016 was required to be $22,250,000, (c) Consolidated Total Revenue of the Borrower for the twelve consecutive month period ended December 31, 2016 was required to be $24,600,000, (d) Consolidated Total Revenue of the Borrower for the twelve consecutive month period ended March 31, 2017 was required to be $27,200,000, (e) Consolidated Total Revenue of the Borrower for the twelve consecutive month period ended June 30, 2017 was required to be $30,300,000 and (f) Consolidated Total Revenue of the Borrower for the twelve month period ended September 30, 2017 was required to be $33,800,000;

 

WHEREAS, the Loan Parties have failed to satisfy and comply with requirements of Sections 8.4(a) and (b) set forth in the previous recital;

 

WHEREAS, the Borrower has requested that the Lender temporarily forbear from exercising or pursuing its available remedies as further described herein; and

 

WHEREAS, the Lender is willing to agree to such temporary forbearance subject to the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained herein, the parties agree as follows:

 

 1 

 

 

Article I
definitions

 

SECTION 1.1.      Certain Terms. The following terms (whether or not highlighted in bold and/or italics) when used in this Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

“Agreement” is defined in the preamble.

 

“Borrower” is defined in the preamble.

 

“Credit Agreement” is defined in first recital.

 

“Forbearance Effective Date” is defined in Article III.

 

“Guarantor” is defined in the preamble.

 

“Lender” is defined in the preamble.

 

“Loan Party” is defined in the preamble.

 

“Specified Defaults” is defined in Section 2.1(a).

 

“Termination Date” is defined in Section 2.1(b).

 

Article II
FORBEARANCE, ETC.

 

SECTION2.1.      Forbearance, etc.

 

(a)               The Borrower acknowledges and agrees that it was in Default of (i) Section 8.4(a) of the Credit Agreement as of the date hereof and (ii) Section 8.4(b) of the Credit Agreement as of each of (v) September 30, 2016, (w) December 31, 2016, (x) March 31, 2017, (y) June 30, 2017 and (z) September 30, 2017 (such Defaults being herein referred to as the “Specified Defaults”). The Lender hereby agrees that, with respect to the Specified Defaults (but only the Specified Defaults), it will refrain and forebear from exercising or pursuing any rights or remedies under the Credit Agreement or otherwise (including imposing a default rate of interest in respect of the Specified Defaults pursuant to Section 3.6 of the Credit Agreement) or any other Loan Document until (but only until) the Termination Date. Any term or provision hereof to the contrary notwithstanding, the Lender is not waiving any of its rights or remedies with respect to the Specified Defaults or any other Default, but instead is simply agreeing not to take remedial action with respect to the Specified Defaults until the Termination Date.

 

(b)               The “Termination Date” means the earlier of (i) December 31, 2017 and (ii) the date when the Lender becomes aware that any other Default (other than any Specified Default) has occurred and is continuing. Upon the occurrence of the Termination Date, the Lender may, with respect to any or all of the Specified Defaults, pursue any rights and remedies available to it under the Credit Agreement or any other Loan Document, or pursuant to law or otherwise, with respect to any Defaults that have then occurred and are outstanding (including the Specified Defaults), including, but not limited to, declaring all or any portion of the outstanding principal amount of the Loan and other Obligations to be immediately due and payable, imposing a default rate of interest in respect of the Obligations in accordance with Section 3.6 of the Credit Agreement, or pursuing any or all other rights and remedies of the Lender as a secured party under the UCC, the Pledge and Security Agreement or any other Loan Document.

 

 2 

 

 

(c)               Notwithstanding any provision of this Agreement or any Loan Document to the contrary, each Loan Party hereby acknowledges and agrees that, due to the occurrence and ongoing continuance of the Specified Defaults, the re-investment option set forth in Section 3.4 of the Credit Agreement is not available to any Loan Party, and no Loan Party may re-invest or use any Net Cash Proceeds of any Disposition or Event of Loss as would otherwise be permitted under Section 3.4 of the Credit Agreement if no Default or Event of Default had occurred and was continuing.

 

Article III
conditions precedent

 

This Agreement shall become effective upon, and shall be subject to, the prior or simultaneous satisfaction of each of the following conditions in a manner reasonably satisfactory to the Lender (the date when all such conditions are so satisfied being the “Forbearance Effective Date”):

 

SECTION 3.1.      Counterparts. The Lender shall have received counterparts of this Agreement executed on behalf of the Borrowers, the Guarantor, and the Lender.

 

SECTION 3.2.      Effective Date Certificate. The Lender shall have received a certificate, dated as of the Forbearance Effective Date and duly executed and delivered by an Authorized Officer of the Borrower and each Guarantor certifying as to the matters set forth in Articles IV and V hereof, in form and substance satisfactory to the Lender.

 

SECTION 3.3.      Costs and Expenses, etc. The Lender shall have received all fees, costs and expenses due and payable pursuant to Section 11.3 of the Credit Agreement (including without limitation the reasonable fees and expenses of Morrison & Foerster LLP, counsel to the Lender), if then invoiced, together with any other fees separately agreed to by the Borrower and the Lender, such fees, costs and expenses; provided, however, that the Borrower shall be not be required to reimburse Lender for fees and expenses of Morrison & Foerster LLP in excess of $8,000 .

 

SECTION 3.4.      Satisfactory Legal Form, etc. All legal matters incident to the effectiveness of this Agreement shall be reasonably satisfactory to the Lender and its counsel.

 

Article IV
Representations and Warranties

 

To induce the Lender to enter into this Agreement, each Loan Party represents and warrants to the Lender as set forth below.

 

SECTION 4.1.      Validity, etc. This Agreement and the Credit Agreement (after giving effect to this Agreement) each constitutes the legal, valid and binding obligation of each Loan Party, enforceable in accordance with its respective terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

 3 

 

 

SECTION 4.2.      Representations and Warranties, etc. Immediately prior to, and immediately after giving effect to, this Agreement the following statements shall be true and correct:

 

(a)      the representations and warranties set forth in each Loan Document (as defined in the Credit Agreement) shall, in each case, be, in the case of representations and warranties qualified as to knowledge, materiality, Material Adverse Effect (as defined in the Credit Agreement) or any similar qualification, true and correct in all respects, and, in the case of those representations and warranties that are not so qualified, in all material respects, with the same effect as if then made (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date); and

 

(b)      no Default (other than the Specified Defaults) shall have then occurred and be continuing.

 

Article V
Confirmation

 

SECTION 5.1.      Reaffirmation. Each Loan Party hereby consents to this Agreement and hereby agrees that, after giving effect to this Agreement, each Loan Document to which it is a party, and all Obligations thereunder (including the guarantees made pursuant to Article X of the Credit Agreement), are and shall continue to be in full force and effect and the same are hereby ratified in all respects.

 

SECTION 5.2.      Validity, etc. Each Loan Party hereby represents and warrants, as of the Forbearance Effective Date, that immediately after giving effect to this Agreement, each Loan Document, in each case as modified by this Agreement (where applicable and whether directly or indirectly), to which it is a party continues to be a legal, valid and binding obligation of such Loan Party, enforceable against such Person in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

Article VI
Miscellaneous

 

SECTION 6.1.      No Waiver. The Lender’s agreement not to pursue its rights and remedies until the occurrence of the Termination Date as described in Section 2.1 herein is temporary and limited in nature. Except as expressly provided herein, (i) nothing contained herein shall be deemed to constitute a waiver of the Specified Defaults or any other Default or Event of Default or compliance with any term or condition contained in the Credit Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties and (ii) the Lender reserves all rights, privileges and remedies under the Credit Agreement and the other Loan Documents.

 

 4 

 

 

SECTION 6.2.      Severability. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

SECTION 6.3.      Integration. This Agreement, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.

 

SECTION 6.4.      Cross-References; Headings. References in this Agreement to any Article or Section are, unless otherwise specified, to such Article or Section of this Agreement. Headings and captions used in this Agreement are included for convenience of reference only and shall not be given any substantive effect.

 

SECTION 6.5.      Loan Document Pursuant to Credit Agreement. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated therein) be construed, administered and applied in accordance with all of the terms and provisions of the Credit Agreement, including Article XI thereof and all rules of interpretation set forth in Article I thereof.

 

SECTION 6.6.      Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

SECTION 6.7.      Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart.  Delivery of an executed counterpart of a signature page to this Agreement by facsimile (or other electronic transmission) shall be effective as delivery of a manually executed counterpart of this Agreement.

 

SECTION 6.8.      Governing Law. This AGREEMENT shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

 

SECTION 6.9.      Full Force and Effect. The Loan Parties each jointly and severally agree that all of the representations, warranties, terms, covenants, conditions and other provisions of the Credit Agreement and the other Loan Documents shall remain unmodified and shall continue to be, and shall remain, in full force and effect in all respects. 

 

[Signature pages to follow]

 5 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

  

  BORROWER:
     
  ALLIQUA BIOMEDICAL, INC.,
   
  By ___________________________
  Name:
  Title:
   
  GUARANTOR:
   
  AQUAMED TECHNOLOGIES, INC.,
   
  By ___________________________
  Name:
  Title:

 

 

 6 

 

 

 

LENDER:

 


PERCEPTIVE CREDIT HOLDINGS, LP

 

By Perceptive Credit Opportunities GP, LLC,
its general partner

 

By _____________________________

Sandeep Dixit

Chief Credit Officer

 

By _____________________________
Name:
Title:

 

 7 

 EX-31.1 3 tv478458_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14(A) AND 15d-14(A)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, David Johnson, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Alliqua BioMedical, Inc. (the “registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

  

Date: November 9, 2017 By: /s/ David Johnson
    David Johnson
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 EX-31.2 4 tv478458_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(A) AND 15d-14(A)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Brian M. Posner, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Alliqua BioMedical, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

  

Date: November 9, 2017 By: /s/ Brian M. Posner
    Brian M. Posner
    Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 EX-32.1 5 tv478458_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the three months ended September 30, 2017, of Alliqua BioMedical, Inc. (the “Company”). I, David Johnson, the Chief Executive Officer and Principal Executive Officer of the Company, certify that, based on my knowledge:

 

(1)The Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: November 9, 2017 By: /s/ David Johnson
  Name:  David Johnson
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-Q pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-Q for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 EX-32.2 6 tv478458_ex32-2.htm EXHIBIT 32.2

 

EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the three months ended September 30, 2017 of Alliqua BioMedical, Inc. (the “Company”). I, Brian M. Posner, the Chief Financial Officer and Principal Financial Officer of the Company, certify that, based on my knowledge:

 

(1)The Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: November 9, 2017 By: /s/ Brian M. Posner
  Name:  Brian M. Posner
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-Q pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-Q for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 EX-101.INS 7 alqa-20170930.xml XBRL INSTANCE DOCUMENT 0001054274 2016-01-01 2016-09-30 0001054274 2016-01-01 2016-12-31 0001054274 2017-01-01 2017-09-30 0001054274 2017-02-01 2017-02-27 0001054274 2016-04-01 2017-03-31 0001054274 2017-06-01 0001054274 2016-07-01 2017-06-30 0001054274 2016-07-01 2016-09-30 0001054274 2017-07-01 2017-09-30 0001054274 2017-08-31 0001054274 2016-09-30 0001054274 2017-09-30 0001054274 2017-11-08 0001054274 2012-11-30 0001054274 2016-12-31 0001054274 2015-12-31 0001054274 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001054274 us-gaap:FairValueInputsLevel3Member alqa:WarrantLiabilityMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001054274 us-gaap:FairValueInputsLevel3Member alqa:WarrantLiabilityMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001054274 us-gaap:FairValueInputsLevel3Member alqa:WarrantLiabilityMember 2017-01-01 2017-09-30 0001054274 us-gaap:FairValueInputsLevel3Member us-gaap:MinimumMember alqa:WarrantLiabilityMember 2017-01-01 2017-01-26 0001054274 us-gaap:FairValueInputsLevel3Member us-gaap:MaximumMember alqa:WarrantLiabilityMember 2017-01-01 2017-01-26 0001054274 us-gaap:FairValueInputsLevel3Member alqa:WarrantLiabilityMember 2017-01-01 2017-01-26 0001054274 alqa:PrivatePlacement2017Member us-gaap:MinimumMember 2012-11-30 0001054274 alqa:PrivatePlacement2017Member us-gaap:MaximumMember 2012-11-30 0001054274 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001054274 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001054274 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001054274 us-gaap:FairValueInputsLevel1Member 2017-09-30 0001054274 us-gaap:FairValueInputsLevel2Member 2017-09-30 0001054274 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001054274 alqa:ContingentConsiderationMember 2016-12-31 0001054274 alqa:ContingentConsiderationMember 2017-01-01 2017-09-30 0001054274 alqa:ContingentConsiderationMember 2017-09-30 0001054274 alqa:ContingentConsiderationMember 2015-12-31 0001054274 alqa:ContingentConsiderationMember 2016-01-01 2016-09-30 0001054274 alqa:ContingentConsiderationMember 2016-09-30 0001054274 us-gaap:PrivatePlacementMember 2017-02-01 2017-02-27 0001054274 us-gaap:PrivatePlacementMember 2017-02-27 0001054274 alqa:SecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2017-06-23 0001054274 alqa:SecuritiesPurchaseAgreementMember 2017-04-01 2017-04-11 0001054274 alqa:UnderwrittenPublicOfferingMember 2017-04-01 2017-04-03 0001054274 alqa:UnderwrittenPublicOfferingMember 2017-04-03 0001054274 us-gaap:WarrantMember 2017-04-03 0001054274 alqa:UnderwrittenPublicOfferingMember 2012-11-08 0001054274 alqa:November2012WarrantsMember 2017-04-03 0001054274 us-gaap:CostOfSalesMember 2017-07-01 2017-09-30 0001054274 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001054274 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001054274 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001054274 us-gaap:RestrictedStockMember 2017-09-30 0001054274 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001054274 us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0001054274 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001054274 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001054274 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001054274 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-09-30 0001054274 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-09-30 0001054274 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-09-30 0001054274 us-gaap:RestrictedStockMember us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-01-01 2017-09-30 0001054274 alqa:UnderwrittenPublicOfferingMember alqa:NonExecutiveEmployeesMember 2017-06-02 2017-06-27 0001054274 alqa:HumanLongevityIncMember 2017-07-01 2017-09-30 0001054274 alqa:HumanLongevityIncMember 2016-07-01 2016-09-30 0001054274 alqa:HumanLongevityIncMember 2017-01-01 2017-09-30 0001054274 alqa:HumanLongevityIncMember 2016-01-01 2016-09-30 0001054274 alqa:HumanLongevityIncMember 2017-09-30 0001054274 alqa:HumanLongevityIncMember 2016-09-30 0001054274 alqa:HumanLongevityIncMember alqa:FirstCommercialSaleMember 2017-09-30 0001054274 alqa:HumanLongevityIncMember alqa:SecondCommercialSaleMember 2017-09-30 0001054274 alqa:ContingentConsiderationMember alqa:InstallmentOneMember 2016-01-01 2016-03-31 0001054274 alqa:ContingentConsiderationMember alqa:InstallmentOneMember 2016-03-31 0001054274 alqa:InstallmentOneMember alqa:TwoThousandFifteenMistTherapyMember 2016-01-01 2016-03-31 0001054274 alqa:InstallmentOneMember alqa:TwoThousandFourteenMistTherapyMember 2016-01-01 2016-03-31 0001054274 alqa:InstallmentTwoMember alqa:ContingentConsiderationMember 2017-03-31 0001054274 alqa:InstallmentTwoMember 2017-01-01 2017-03-31 0001054274 alqa:TwoThousandSixteenMistTherapyMember alqa:InstallmentTwoMember 2017-01-01 2017-03-31 0001054274 alqa:TwoThousandFifteenMistTherapyMember alqa:InstallmentTwoMember 2017-01-01 2017-03-31 0001054274 alqa:SeniorSecuredDebtMember 2015-05-29 0001054274 us-gaap:InterestExpenseMember 2017-07-01 2017-09-30 0001054274 alqa:SeniorSecuredDebtMember 2017-01-01 2017-09-30 0001054274 us-gaap:InterestExpenseMember 2016-07-01 2016-09-30 0001054274 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2017-09-30 0001054274 us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0001054274 us-gaap:InterestExpenseMember 2016-01-01 2016-09-30 0001054274 alqa:CreditAgreementMember 2015-10-01 2016-09-30 0001054274 alqa:CreditAgreementMember 2016-01-01 2016-12-31 0001054274 alqa:CreditAgreementMember 2016-04-01 2017-03-31 0001054274 alqa:CreditAgreementMember 2016-07-01 2017-06-30 0001054274 us-gaap:BridgeLoanMember 2017-01-01 2017-09-30 0001054274 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2017-09-30 0001054274 us-gaap:BridgeLoanMember 2016-10-05 0001054274 us-gaap:BridgeLoanMember 2016-12-31 0001054274 us-gaap:BridgeLoanMember 2017-01-30 0001054274 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001054274 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001054274 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001054274 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001054274 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001054274 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001054274 us-gaap:SubsequentEventMember alqa:SolubleSystemsLlcMember 2017-09-28 2017-10-27 0001054274 us-gaap:SubsequentEventMember 2017-10-05 0001054274 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001054274 alqa:PurchaseAgreementMember 2017-01-01 2017-09-30 0001054274 alqa:PurchaseAgreementMember 2017-07-01 2017-09-30 0001054274 alqa:PurchaseAgreementMember 2016-07-01 2016-09-30 0001054274 alqa:PurchaseAgreementMember 2016-01-01 2016-09-30 0001054274 alqa:ArgentumMedicalLlcMember 2017-07-01 2017-09-30 0001054274 alqa:ArgentumMedicalLlcMember 2017-01-01 2017-09-30 0001054274 us-gaap:SubsequentEventMember 2017-10-01 2017-10-05 0001054274 alqa:SeniorSecuredDebtMember 2017-08-01 2017-08-31 0001054274 alqa:SeniorSecuredDebtMember 2017-07-01 2017-09-30 0001054274 alqa:SeniorSecuredDebtMember 2017-08-31 0001054274 alqa:SeniorSecuredDebtMember 2016-01-01 2016-12-31 0001054274 alqa:ChoiceTherapeuticsIncMember 2017-01-01 2017-06-30 0001054274 alqa:ChoiceTherapeuticsIncMember 2017-06-30 0001054274 alqa:ContingentConsiderationMember alqa:InstallmentTwoMember 2017-01-01 2017-03-31 0001054274 alqa:SolubleSystemsLlcMember 2016-01-01 2016-12-31 0001054274 alqa:SolubleSystemsLlcMember 2017-01-01 2017-01-30 0001054274 alqa:SolubleSystemsLlcMember 2017-01-01 2017-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 2106000 5580000 2926000 2453000 1985000 2153000 296000 735000 7777000 11778000 1692000 2092000 23202000 26604000 11959000 11959000 173000 173000 44803000 54499000 1603000 2614000 0 675000 419000 20000 16671000 20134000 0 1141000 758000 749000 316000 385000 17745000 22409000 0 0 5000 3000 165256000 156390000 -138203000 -124303000 27058000 32090000 44803000 54499000 3876000 5224000 10736000 11541000 55.10 6629 246231 0.7263 1.3185 0.0096 0.0177 P1M6D P4Y3M25D 0.00 210000 0.6533 0.7898 0.0149 0.0195 P3Y4M2D P5Y 0.00 5.00 4.00 29034 36231 0 0 20000 0 0 1836000 0 0 1816000 0 0 419000 0 0 419000 1816000 35000 0 17028000 -8634000 3247000 1851000 5147000 -404000 -797000 20000 861000 803000 0 100000 28000 39000 102000 286000 554000 5.00 196000 40000 2800000 100429 38072 947325 4.00 3800000 365000 92000 23684 4.40 78000 21.90 4.00 36230 686000 1200000 1000 5000 687000 1200000 1400000 P9M18D 4300000 25000 134000 4100000 181936 621000 66936 5000 50000 60000 208050 3.50 519000 199000 121000 591000 296000 199000 197000 500000 500000 1000000 2600000 98600 2600000 3.5 10200000 8700000 675000 3.5 10500000 10200000 15500000 61000 1300000 64000 0.001 55.138 75000 2700000 0.1100 190000 209000 24600000 27200000 30300000 33800000 1399000 2211000 10736000 11541000 12135000 13752000 4.70 1713000 3007000 483000 692000 200000 197000 141000 147000 3876000 5224000 339000 181000 1000000 1000000 115000 135000 39000 173000 1843000 1845000 12000 0 285000 0 1400000 1000000 350000 1588417 1217725 879182 514561 194674 733862 336541 147322 24600000 27200000 30300000 603000 3500000 4103000 3311000 792000 603000 189000 112000 3600000 3712000 1700000 2012000 303000 1709000 499000 157000 342000 175000 167000 3155000 999000 2156000 863000 1293000 346000 113000 233000 100000 133000 1255000 397000 858000 392000 466000 74000 260000 -11098000 4111000 3124000 9000 9000 1604000 4268000 -797000 35000 -8634000 499000 254000 -414000 643000 -439000 -55000 -1023000 -48000 -1000000 1297000 -9799000 -14034000 126000 573000 151000 2000 3389000 -4375000 -3474000 -15379000 26080000 10701000 169000 631000 636000 37000 1175000 2574000 1008000 1221000 2936000 3030000 12000 -54000 2000 84000 5865000 0 0 474000 34000 23000 350000 0 374000 0 14108000 4765000 9343000 21729000 635000 23113000 -13770000 1746000 5000 -404000 -2287000 9000 -13900000 11851000 4493000 7358000 27019000 819000 21642000 -14284000 1957000 24000 -1409000 9000 121000 692000 -16057000 -15693000 -16066000 -15702000 -3.89 -5.63 0.11 0.46 593000 746000 4901000 1538000 3363000 7004000 0 0 7205000 -3842000 577000 1000 -35000 -688000 3000 -2700000 4375000 1608000 2767000 8458000 715000 97000 10705000 -7938000 685000 9000 -135000 -814000 3000 -8588000 1000 164000 -4530000 -8752000 -4533000 -8755000 -0.95 -3.11 0.03 0.06 200000 271000 0 0 1833000 167000 2166000 4604000 0.36 0 0.41 1.19 0.39 0.06 0.52 1.65 1700000 0 10-Q false 2017-09-30 2017 Q3 Alliqua BioMedical, Inc. 0001054274 --12-31 Smaller Reporting Company ALQA 4986034 464000 857000 0 1893000 37000 60000 0.001 0.001 1000000 1000000 0 0 0 0 0.001 95000000 95000000 4988244 4988244 2966904 2966904 0 0 1000000 -214000 -373000 -214000 67000 100000 67000 1000000 -373000 100000 4753789 2819567 4125653 2788696 0 3000 321000 182000 0 1000000 3412000 4103000 1618000 1748000 32000 52000 0 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 1.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Description of Business and Basis of Presentation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Alliqua BioMedical, Inc. (the &#8220;Company&#8221;) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company&#8217;s financial position as of September 30, 2017 and results of operations and cash flows for the three and nine months ended September 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company&#8217;s latest year-end financial statements, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016 (the &#8220;2016 Annual Report&#8221;).&#160;&#160;The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Reclassifications</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company&#8217;s financial condition or results of operations as previously reported.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Reverse Stock Split</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company effected a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1-for-10</font> reverse stock split of its outstanding common stock on October 5, 2017. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share. Accordingly, stockholders&#8217; equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Discontinued Operations</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective August 31, 2017, the Company entered into an Asset Purchase Agreement (&#8220;the Asset Purchase Agreement&#8221;) with Argentum Medical, LLC. (&#8220;Argentum&#8221;) whereby the Company agreed to sell to Argentum all of the Company&#8217;s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Asset Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.6</font> million for the TheraBond product line and certain other agreements between the parties and (ii) up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">112,000</font> for the unsold TheraBond inventory upon the Company&#8217;s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Asset Purchase Agreement. Of the $3.6 million of consideration, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company&#8217;s balance sheet as of September 30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Additionally, effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (&#8220;BSN&#8221;) whereby the Company agreed to sell to BSN all of the Company&#8217;s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH &amp; Co KG.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The results of operations for the three and nine months ended September 30, 2017 and 2016 reflect the Company&#8217;s continuing operations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenue, net of returns, allowances and discounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>346</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,255</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cost of revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>858</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Selling, general and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Income from discontinued operations, net of tax</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>466</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Non-cash amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">74,000</font> is included in selling, general and administrative expense for the three months ended September 30, 2017 and 2016, respectively. Non-cash amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">260,000</font> is included in selling, general and administrative expense for the nine months ended September 30, 2017 and 2016, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,712</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to Argentum</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(303)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,709)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,012)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the nine months ended September 30, 2016, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.3</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>603</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to BSN</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(603)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(792)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts receivable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>164</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Escrow</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>857</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (&#8220;Transition Agreement&#8221;). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum will pay the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. One-third of this compensation ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67,000</font></font>) was recognized and is included in other income for the three and nine months ended September 30, 2017.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Significant Accounting Policies and Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company&#8217;s significant accounting policies are disclosed in Note 2 &#151; <i>Summary of Significant Accounting Policies</i> in the 2016 Annual Report. Since the date of the 2016 Annual Report, there have been no material changes to the Company&#8217;s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.&#160;&#160;These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recent Accounting Principles</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; (&#8220;ASU 2014-09&#8221;). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, &#8220;Revenue Recognition&#8221; and some cost guidance included in ASC Subtopic 605-35, &#8220;Revenue Recognition - Construction-Type and Production-Type Contracts.&#8221; The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company&#8217;s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, &#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221; which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, &#8220;Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),&#8221; was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, &#8220;Identifying Performance Obligations and Licensing,&#8221; issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, &#8220;Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients&#8221; provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, &#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,&#8221; was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (&#8220;ASU 2017-09&#8221;). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basis of Presentation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company&#8217;s financial position as of September 30, 2017 and results of operations and cash flows for the three and nine months ended September 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company&#8217;s latest year-end financial statements, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016 (the &#8220;2016 Annual Report&#8221;).&#160;&#160;The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Principles of Consolidation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Reclassifications</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company&#8217;s financial condition or results of operations as previously reported.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Discontinued Operations</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective August 31, 2017, the Company entered into an Asset Purchase Agreement (&#8220;the Asset Purchase Agreement&#8221;) with Argentum Medical, LLC. (&#8220;Argentum&#8221;) whereby the Company agreed to sell to Argentum all of the Company&#8217;s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Asset Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.6</font> million for the TheraBond product line and certain other agreements between the parties and (ii) up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">112,000</font> for the unsold TheraBond inventory upon the Company&#8217;s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Asset Purchase Agreement. Of the $3.6 million of consideration, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company&#8217;s balance sheet as of September 30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Additionally, effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (&#8220;BSN&#8221;) whereby the Company agreed to sell to BSN all of the Company&#8217;s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH &amp; Co KG.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The results of operations for the three and nine months ended September 30, 2017 and 2016 reflect the Company&#8217;s continuing operations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenue, net of returns, allowances and discounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>346</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,255</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cost of revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>858</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Selling, general and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Income from discontinued operations, net of tax</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>466</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Non-cash amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">74,000</font> is included in selling, general and administrative expense for the three months ended September 30, 2017 and 2016, respectively. Non-cash amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">260,000</font> is included in selling, general and administrative expense for the nine months ended September 30, 2017 and 2016, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,712</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to Argentum</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(303)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,709)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,012)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the nine months ended September 30, 2016, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.3</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>603</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to BSN</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(603)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(792)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts receivable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>164</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Escrow</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>857</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (&#8220;Transition Agreement&#8221;). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum will pay the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. One-third of this compensation ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67,000</font></font>) was recognized and is included in other income for the three and nine months ended September 30, 2017.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Significant Accounting Policies and Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company&#8217;s significant accounting policies are disclosed in Note 2 &#151; <i>Summary of Significant Accounting Policies</i> in the 2016 Annual Report. Since the date of the 2016 Annual Report, there have been no material changes to the Company&#8217;s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.&#160;&#160;These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Recent Accounting Principles</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; (&#8220;ASU 2014-09&#8221;). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, &#8220;Revenue Recognition&#8221; and some cost guidance included in ASC Subtopic 605-35, &#8220;Revenue Recognition - Construction-Type and Production-Type Contracts.&#8221; The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company&#8217;s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, &#8220;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221; which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, &#8220;Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),&#8221; was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, &#8220;Identifying Performance Obligations and Licensing,&#8221; issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, &#8220;Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients&#8221; provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, &#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,&#8221; was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (&#8220;ASU 2017-09&#8221;). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenue, net of returns, allowances and discounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>346</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,255</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cost of revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Gross profit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>858</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Selling, general and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Income from discontinued operations, net of tax</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>466</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts receivable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>164</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Escrow</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>857</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,712</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to Argentum</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(303)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,709)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,012)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the nine months ended September 30, 2016, the Company recorded a gain of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.3</font></font> million (net of tax of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Proceeds from sale</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>603</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Consideration for intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: Net book value of assets sold to BSN</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(603)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Intangibles, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total net book value of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(792)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Gain on sale of assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 12.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Subsequent Event</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company advanced Soluble&#160;$1.4 million,&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million during the year ended December 31, 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> on January 30, 2017.&#160;</div> &#160; <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On October 27, 2017, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million under an agreement with Soluble in connection with amounts advanced to Soluble by the Company. With the receipt of this $1 million, the Company acknowledged that all amounts due to the Company from Soluble are paid in full.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 164000 307000 0 550000 0 1893000 464000 2750000 19000 19000 18000 41000 300000 0 1000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 11.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fair Value Measurement</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 1:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Observable prices in active markets for identical assets and liabilities.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 2:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Observable inputs other than quoted prices in active markets for identical assets and liabilities.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 3:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Warrant Liabilities</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 210,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.70</font> per share. See Note 7 &#150; <i>Debt</i> for additional details. In connection with the amendments of January, March, April and June 2017, the Company recomputed the fair value of the original warrant and amended warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65.33</font>%-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">78.98</font>%, risk-free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.49</font>%-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.95</font>%, expected term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.34</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> years, and expected dividends of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.00</font>%. As a result, the Company recorded warrant modification expense of $0 and $803,000 during the three and nine months ended September 30, 2017, respectively, which represents the incremental value of the amended warrant as compared to the original warrant, both valued as of the respective amendment dates.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On September 30, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 246,231</font> shares of common stock as $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">419,000</font> using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 72.63</font>%-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">131.85</font>%, risk-free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.96</font>%-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.77</font>%, expected term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.10</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.32</font> years, and expected dividends of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.00</font>%. The Company recorded a gain on the change in fair value of these warrant liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">404,000</font> during the three and nine months ended September 30, 2017, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The issuance of common stock in connection with the Private Placement and Public Offering triggered an adjustment to the exercise price of certain warrants originally issued in November 2012 from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55.10</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font> per share with a corresponding adjustment to the number of shares underlying such warrants from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,629</font> shares to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 29,034</font> shares to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 36,231</font> shares. The impact of such adjustment is included in the change in fair value of the warrant liabilities during the nine months ended September 30, 2017.</font></div> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company&#8217;s Chief Financial Officer and are approved by the Chief Executive Officer.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="55%"> <div>Warrant Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>861</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(404)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(797)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Warrant modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>803</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="55%"> <div>Contingent Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Payments of contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,851)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,147)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Change in fair value of contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(8,634)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>September&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="55%"> <div>Warrant Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>861</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(404)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(797)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Warrant modification expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>803</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="55%"> <div>Contingent Consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Payments of contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,851)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,147)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Change in fair value of contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(8,634)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>September&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,816</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 419000 64000 112000 3600000 0.001 43000 185000 1700000 1700000 3300000 3300000 200000 67000 67000 1-for-10 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Reverse Stock Split</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company effected a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1-for-10</font> reverse stock split of its outstanding common stock on October 5, 2017. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share. Accordingly, stockholders&#8217; equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 2.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Going Concern</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company&#8217;s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, the Company had a cash balance of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million. The Company has experienced recurring losses since its inception. The Company incurred a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.9</font> million and utilized $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.8</font> million in cash from operations for the nine months ended September 30, 2017, and had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">138.2</font> million as of September 30, 2017. As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement (as defined in <i> Note 7- Debt</i>) as a result of the Company&#8217;s failure to achieve $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,600,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,200,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,300,000</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,800,000</font> of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017, respectively. Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive Credit Opportunities Fund, L.P. (&#8220;Perceptive&#8221;) entered into a Consent, Forbearance and Amendment Agreement (the &#8220;Consent and Forbearance Agreement&#8221;), pursuant to which the Company agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,650,000</font> of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,618,000</font> was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,000</font> was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,000</font></font> prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font></font> of unamortized debt issuance costs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company&#8217;s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">the Company&#8217;s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font>, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default.</font> On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company&#8217;s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender&#8217;s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company&#8217;s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company&#8217;s assets after the expiration of the forbearance. Such action could hinder the Company&#8217;s ability to recover the remaining carrying value of some or all of its intangible assets including goodwill that aggregated approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35.2</font> million at September 30, 2017. These factors raise substantial doubt as to the Company&#8217;s ability to continue as a going concern within one year from the date of this filing. The ability of the Company to continue as a going concern is dependent upon the Company&#8217;s successful efforts to raise sufficient capital and attain profitable operations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Management is evaluating all options to raise sufficient funds to meet its outstanding debt obligations and to fund the Company&#8217;s working capital requirements. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 33800000 1650000 1618000 32000 32000 53000 32000 53000 the Companys default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. 358000 35200000 2000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 9.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Stockholders&#8217; Equity</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Private Placement</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On February 27, 2017, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the &#8220;Private Placement&#8221;) an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 554,000</font> shares of the Company&#8217;s common stock at a purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share. The Company closed the Private Placement on the same day as it entered into the Securities Purchase Agreement and received aggregate gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.8</font> million. In connection with the Private Placement, the Company paid an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">196,000</font> of financial advisory fees and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> of administrative fees, which were recorded as a reduction of additional paid-in capital.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Securities Purchase Agreement contains a &#8220;most-favored nation&#8221; provision that provides that if the Company, during 120 days from February 27, 2017, issues or sells any common stock or common stock equivalents reasonably believed to be more favorable in terms or conditions than those in the Private Placement, then the Company must amend the terms of the Securities Purchase Agreement to give the private investors the benefit of such favorable terms or conditions. In connection with the common stock sold in the Public Offering (as defined below) and in accordance with this provision, on April 11, 2017, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38,072</font> shares of its common stock to these investors. On June 23, 2017, the Company held its 2017 annual meeting of stockholders during which the stockholders approved the issuance of the remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,429</font> additional shares of common stock to be issued to the investors, and, following the meeting, on June 23, 2017, the Company issued the remaining shares.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Underwritten Public Offering</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On April 3, 2017, the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;) of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 947,325</font> shares of its common stock at a price to the public of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font> per share. The Company received aggregate gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million. In connection with the Public Offering, the Company paid an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">365,000</font> of financial advisory fees and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">92,000</font> of administrative fees, which were recorded as a reduction of additional paid-in capital. The shares of common stock were issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September&#160;25, 2014.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On April 3, 2017, the Company issued warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,684</font> shares of the Company&#8217;s common stock to the underwriter of this offering. These warrants are immediately exercisable, have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.40</font>, and expire on March 29, 2022. The warrants had an aggregate issuance date fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">78,000</font> which was recorded as both a debit and credit to additional paid in capital.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21.90</font>, the exercise price of these warrants was adjusted to the public offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font>. As of April 3, 2017, November 2012 warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 36,230</font> shares of the Company&#8217;s common stock were outstanding. These warrants expire in November 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">For the three months ended September 30, 2017 and 2016, the Company recognized $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">686,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million of stock-based compensation expense, of which, ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font>) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> is included in cost of revenues and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">687,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. For the nine months ended September 30, 2017 and 2016, the Company recognized $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.3</font> million of stock-based compensation expense, of which, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">134,000</font> is included in cost of revenues and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.1</font> million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. As of September 30, 2017, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million of unrecognized stock-based compensation expense which will be amortized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.8</font> years.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock Options</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 27, 2017, the Company granted non-executive employees ten-year options to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 208,050</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.50</font> per share. The aggregate grant date value of the options is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">519,000</font>. The options vest in one-fourth increments every six months over a period of two years.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Restricted Stock</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the nine months ended September 30, 2017, the Company granted an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 181,936</font> shares of restricted stock to employees with an aggregate grant date value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">621,000</font> which will be recognized proportionate to the vesting period. The shares vest as follows: (i) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66,936</font> shares vested on September 21, 2017, (ii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000</font> shares vest on December 31, 2017, (iii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares vest on June 23, 2018, and (iv) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> shares vest pursuant to the satisfaction of certain performance conditions.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 3.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Net Loss Per Common Share</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basic (loss) income per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted (loss) income per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div> Nine&#160;Months&#160;Ended&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>879,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>733,862</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>514,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>336,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Non-vested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>194,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,588,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,217,725</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div> Nine&#160;Months&#160;Ended&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>879,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>733,862</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>514,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>336,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Non-vested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>194,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,588,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,217,725</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 7.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Debt</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Senior Secured Term Loan Facility</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) with Perceptive Credit Opportunities Fund, L.P. (&#8220;Perceptive&#8221;). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.5</font> million. The Credit Agreement (i) has a four-year term, (ii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>, (iii)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> and (iv) is secured by a first priority lien on substantially all of the Company&#8217;s assets. The payment of principal under the Credit Agreement has been deferred until January 31, 2018, see Consent and Forbearance Agreement below. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> The interest rate at September 30, 2017 was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11.00</font>%.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the Credit Agreement, the Company incurred approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million of debt issuance costs. The debt issuance costs are being amortized over the term of the loan on a straight-line basis, which approximates the effective interest method. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">61,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font>, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">190,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">209,000</font>, respectively, which is included in interest expense.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the entry into the Credit Agreement, a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>five-year warrant<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> (the &#8220;Warrant&#8221;) to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75,000</font> shares of common stock, par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55.138</font> per share (the &#8220;Exercise Price&#8221;) was issued to Perceptive. The Company granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. The Warrant contains a weighted average anti-dilution feature whereby the Exercise Price is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current Exercise Price. As a result, the Warrant was determined to be a derivative liability. The Warrant had an issuance date fair value of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.7</font> million which was recorded as a debt discount. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $144,000 and $143,000, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $441,000 and $427,000, respectively, which is included in interest expense for the periods presented. See Note 11 &#150; <i>Fair Value Measurement</i> for additional details.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company&#8217;s failure to achieve $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,600,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,200,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,300,000</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,800,000</font> of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017, respectively. The Company has classified the entire principal balance as a current liability in its balance sheet as of September 30, 2017 and December 31, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the Warrant. The amended and restated Warrant, as amended, is exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 210,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.70</font>. The amended and restated Warrant, as amended, contains a weighted average anti-dilution feature whereby the exercise price of the amended and restated warrant is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current exercise price of such warrant. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. See Note 11 &#150; <i>Fair Value Measurement</i> for additional details.</font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Debt consists of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Principle balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Unamortized debt issuance and discount costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,399)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,211)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Consent and Forbearance Agreement</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive entered into a Consent, Forbearance and Amendment Agreement (the &#8220;Consent and Forbearance Agreement&#8221;), pursuant to which the Company agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,650,000</font> of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,618,000</font> was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,000</font> was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,000</font></font> prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font></font> of unamortized debt issuance costs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company&#8217;s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Company&#8217;s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default.</font> On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company&#8217;s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender&#8217;s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company&#8217;s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company&#8217;s assets after the expiration of the forbearance.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Debt consists of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Principle balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Unamortized debt issuance and discount costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,399)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,211)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 4.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Termination of Merger Agreement</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (&#8220;Soluble&#8221;) through a series of transactions. On February 27, 2017, the Company terminated this agreement.,</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the merger agreement to acquire the business of Soluble, the Company provided Soluble with bridge loans in the form of subordinated promissory notes totaling approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million.&#160; The Company advanced Soluble $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million during the year ended December 31, 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> on January 30, 2017.&#160; Pursuant to the terms of the merger agreement, the amount was to be repaid in full upon termination of the agreement.&#160; As of September 30, 2017, the Company fully reserved the amount due. As of December 31, 2016, the Company had provided for a full reserve for the amount that had been advanced to Soluble as of that date.&#160; The Company recorded bad debt expense of $350,000 during the nine months ended September 30, 2017. This expense is included in acquisition related expense. The Company also incurred approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">285,000</font> of other acquisition related expenses related to the Soluble transaction during the nine months period ended September 30, 2017.&#160;The net balance of the note receivable is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and is included in prepaid and other current assets as of September 30, 2017 and December 31, 2016.&#160; See Note 12 - Subsequent Event.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Inventory</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventory consists of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>173</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,843</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less: Inventory reserve for excess and slow moving inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(12)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,153</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000. five-year warrant accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75% <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inventory consists of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>173</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,843</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,845</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less: Inventory reserve for excess and slow moving inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(12)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,153</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 6.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accrued Expenses and Other Current Liabilities</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accrued expenses and other current liabilities consist of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Salaries, benefits and incentive compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,713</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,007</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Milestone payment to licensor</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>692</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Royalty fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,224</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1600000 The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Salaries, benefits and incentive compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,713</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,007</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Milestone payment to licensor</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>692</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Royalty fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,224</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1600000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 8.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Commitments and Contingencies</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Agreements for Human Placental Based Products</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Human Longevity, Inc.</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2013, the Company entered into a License, Marketing and Development Agreement (the &#8220;License Agreement&#8221;) and Supply Agreement (the &#8220;Biovance Supply Agreement&#8221;) with Celgene Cellular Therapeutics (&#8220;CCT&#8221;), an affiliate of Celgene Corporation (&#8220;Celgene&#8221;). The agreements grant the Company an exclusive, royalty-bearing license in CCT&#8217;s intellectual property for certain placental based products, including ECM and Biovance &#174;, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, HLI Cellular Therapeutics, LLC (&#8220;HLI&#8221;), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. In June 2017, Celularity, Inc. (&#8220;Celularity&#8221;) acquired all of the assets of HLI, including the agreements between HLI and the Company. The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. For the three months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">199,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">121,000</font>, respectively, in connection with this agreement. For the nine months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">591,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">296,000</font>, respectively, in connection with this agreement. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">199,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">197,000</font> is included in accrued expenses as of September 30, 2017 and December 31, 2016, respectively, in connection with this agreement. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The License Agreement with Celularity is terminable on a product-by-product basis if the Company fails to meet certain minimum sales thresholds in the second year or any subsequent year of commercial sales of each licensed product. Each year of commercial sales are referred to in the License Agreement as &#8220;launch years&#8221; and the calendar period constituting each launch year for each licensed product is determined in accordance with the terms of the License Agreement. To maintain its license for Biovance, the Company must meet a minimum gross sales amount for Biovance in the second year and third year of commercial sales. If the Company fails to meet the minimum threshold in the second year of commercial sales of product, it would be able to cure such failure by making a cure payment specified in the License Agreement to Celularity; provided, however, the Company does not have the option to make a cure payment, should it fail to meet the minimum threshold for such product in the third year of commercial sales and Celularity may terminate the License Agreement with respect to such product.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In September 2014, the Company entered into a First Amendment to the License Agreement (the &#8220;Amended License Agreement&#8221;), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT&#8217;s connective tissue matrix product, also known as Interfyl.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In April 2016, the Company entered into a Supply Agreement with HLI (now Celularity), pursuant to which Celularity supplies the Company with the Company&#8217;s entire requirement of Interfyl&#153; Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay Celularity $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> related to the first commercial sale of Interfyl in the flowable matrix configuration and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> related to the first commercial sale of Interfyl in the particulate form. Commercial sales of both configurations occurred in September 2016, and as such, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million of milestone expense during the year ended December 31, 2016. The milestone has been included in accrued expenses and other current liabilities as of September 30, 2017 and December 31, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Contingent Consideration</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Celleration, Inc.</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (&#8220;Celleration&#8221;), a medical device company focused on developing and commercializing the MIST Therapy&#174; therapeutic ultrasound platform for the treatment of acute and chronic wounds. The Company agreed to pay contingent consideration of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.5</font> times revenue from acquired MIST Therapy products in excess of certain revenue targets for the years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Company&#8217;s common stock. This contingent consideration was payable in two installments in March 2016 and March 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The first installment consisted of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.6</font> million of cash and approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 98,600</font> shares of the Company&#8217;s common stock valued at approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.6</font> million and was paid in March 2016. This payment was based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.5</font> times of the excess of 2015 MIST Therapy revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.2</font> million over 2014 MIST Therapy revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.7</font> million.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The second installment consisted of $675,000 of cash and approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of the Company&#8217;s common stock valued at approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font> and was paid in March 2017. This payment was based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.5</font> times of the excess of 2016 MIST Therapy revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.5</font> million over 2015 MIST Therapy revenue of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.2</font> million. There are no further contingent payments due in connection with the Celleration acquisition.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Choice Therapeutics, Inc.</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D&#174; Antimicrobial Barrier Systems. The Company agreed to pay contingent consideration based upon the Company achieving specific performance metrics over the three twelve-month periods, ended April 30, 2017. The Company issued approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 130,000</font> shares of its common stock valued at approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> in June 2017. There are no further contingent payments due in connection with the Choice acquisition.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Litigation, Claims and Assessments</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2017.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 130000 500000 P4Y 100000 2022-03-29 -0.56 -3.05 -3.37 -3.98 214000 214000 350000 500000 350000 129000 129000 144000 143000 441000 427000 675000 675000 2573000 0 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>10.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Related Party</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then a member of the Board of Directors. During the three months ended September 30, 2017 and 2016, the Company incurred costs of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>, respectively, from this vendor. During the nine months ended September 30, 2017 and 2016, the Company incurred costs of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">286,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">358,000</font>, respectively, from this vendor. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">102,000</font> is included in accounts payable related to this related party as of September 30, 2017 and December 31, 2016, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1000000 350000 1400000 EX-101.SCH 8 alqa-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Net Loss Per Common Share link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Termination of Merger Agreement link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Related Party link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Description of Business and Basis of Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Description of Business and Basis of Presentation (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Description of Business and Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Description of Business and Basis of Presentation (Details 1) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Description of Business and Basis of Presentation (Details 2) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Description of Business and Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Going Concern (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Termination of Merger Agreement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Debt (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Debt (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Fair Value Measurement (Details 1) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Fair Value Measurement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Subsequent Event (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 alqa-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 alqa-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 alqa-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 12 alqa-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Nov. 08, 2017
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q3  
Entity Registrant Name Alliqua BioMedical, Inc.  
Entity Central Index Key 0001054274  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol ALQA  
Entity Common Stock, Shares Outstanding   4,986,034
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 2,106 $ 5,580
Accounts receivable, net 2,926 2,453
Inventory, net 1,985 2,153
Prepaid expenses and other current assets 296 735
Current assets of discontinued operations 464 857
Total current assets 7,777 11,778
Improvements and equipment, net 1,692 2,092
Intangible assets, net 23,202 26,604
Goodwill, net 11,959 11,959
Other assets 173 173
Assets of discontinued operations - noncurrent 0 1,893
Total assets 44,803 54,499
Current Liabilities:    
Accounts payable 1,603 2,614
Accrued expenses and other current liabilities 3,876 5,224
Contingent consideration, current 0 675
Senior secured term loan, net 10,736 11,541
Warrant liability 419 20
Current liabilities of discontinued operations 37 60
Total current liabilities 16,671 20,134
Contingent consideration, long-term 0 1,141
Deferred tax liability 758 749
Other long-term liabilities 316 385
Total liabilities 17,745 22,409
Commitments and Contingencies
Stockholders' Equity    
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding 0 0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 4,988,244 and 2,966,904 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively 5 3
Additional paid-in capital 165,256 156,390
Accumulated deficit (138,203) (124,303)
Total stockholders' equity 27,058 32,090
Total liabilities and stockholders' equity $ 44,803 $ 54,499
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares
Sep. 30, 2017
Dec. 31, 2016
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 95,000,000 95,000,000
Common stock, shares issued 4,988,244 2,966,904
Common stock, shares outstanding 4,988,244 2,966,904
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue, net of returns, allowances and discounts $ 4,901 $ 4,375 $ 14,108 $ 11,851
Cost of revenues 1,538 1,608 4,765 4,493
Gross profit 3,363 2,767 9,343 7,358
Operating expenses        
Selling, general and administrative 7,004 8,458 21,729 27,019
Royalties 200 271 593 746
Research and product development 1 164 121 692
Milestone expense to licensor 0 1,000 0 1,000
Acquisition-related 0 715 635 819
Change in fair value of contingent consideration liability 0 97 35 (8,634)
Total operating expenses 7,205 10,705 23,113 21,642
Loss from operations (3,842) (7,938) (13,770) (14,284)
Other (expense) income        
Interest expense (577) (685) (1,746) (1,957)
Interest income 1 9 5 24
Change in fair value of warrant liability 35 135 404 797
Warrant modification expense 0 0 (803) 0
Loss on early extinguishment of debt, net (214) (373) (214) (373)
Other income 67 100 67 100
Total other expense (688) (814) (2,287) (1,409)
Loss from continuing operations before tax (4,530) (8,752) (16,057) (15,693)
Income tax expense (3) (3) (9) (9)
Loss from continuing operations (4,533) (8,755) (16,066) (15,702)
Discontinued operations:        
Income from discontinued operations, net of tax of $0 for the three and nine months ended September 30, 2017 and 2016 133 167 466 1,293
Gain on sale of assets, net of tax of $0 for the three and nine months ended September 30, 2017 and 2016 1,700 0 1,700 3,311
Income from discontinued operations, net of tax 1,833 167 2,166 4,604
Net loss $ (2,700) $ (8,588) $ (13,900) $ (11,098)
Net loss per basic and diluted common share:        
Loss from continuing operations $ (0.95) $ (3.11) $ (3.89) $ (5.63)
Income from discontinued operations 0.03 0.06 0.11 0.46
Gain on sale of assets 0.36 0 0.41 1.19
Total from discontinued operations 0.39 0.06 0.52 1.65
Net loss per basic and diluted common share $ (0.56) $ (3.05) $ (3.37) $ (3.98)
Weighted average shares used in computing net loss per basic and diluted common share 4,753,789 2,819,567 4,125,653 2,788,696
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period $ 0 $ 0 $ 0 $ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation $ 0 $ 0 $ 0 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating Activities    
Net loss $ (13,900) $ (11,098)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 4,111 3,124
Amortization of deferred lease incentive (34) (23)
Deferred income tax expense 9 9
Provision for doubtful accounts 169 37
Reserve for note receivable 350 0
Provision for excess and slow moving inventory 12 (54)
Stock-based compensation expense 1,604 4,268
Deferred rent 2 84
Accrued interest receivable 0 (3)
Amortization of debt issuance and discount costs 631 636
Loss on early extinguishment of debt 182 321
Warrant modification expense 803 0
Change in fair value of warrant liability (404) (797)
Fair value adjustment of contingent consideration liability 35 (8,634)
Gain on sale of assets (1,700) (3,311)
Changes in operating assets and liabilities:    
Accounts receivable (499) (254)
Inventory 414 (643)
Prepaid expenses and other assets 439 55
Accounts payable (1,023) (48)
Accrued expenses and other current liabilities (1,000) 1,297
Other long-term liabilities 0 1,000
Net Cash Used in Operating Activities (9,799) (14,034)
Investing Activities    
Proceeds from sale of assets 3,412 4,103
Purchase of improvements and equipment (126) (573)
Issuance of bridge loan (350) (500)
Net Cash Provided by Investing Activities 2,936 3,030
Financing Activities    
Contingent purchase price payments (675) (2,573)
Repayment of long-term debt (1,618) (1,748)
Loss on early extinguishment of debt (32) (52)
Net proceeds from issuance of common stock 5,865 0
Payment of withholding taxes related to stock-based employee compensation (151) (2)
Net Cash Provided by (Used in) Financing Activities 3,389 (4,375)
Net Decrease in Cash and Cash Equivalents (3,474) (15,379)
Cash and Cash Equivalents - Beginning of period 5,580 26,080
Cash and Cash Equivalents - End of period 2,106 10,701
Supplemental Disclosure of Cash Flows Information    
Interest 1,008 1,221
Non-cash investing and financing activities:    
2016 Accrued bonus awarded in equity 374 0
2015 Accrued bonus awarded in equity 0 474
Common stock issued for contingent purchase price payments $ 1,175 $ 2,574
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Description and Basis of Presentation [Text Block]
1.
Description of Business and Basis of Presentation
 
Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue.
 
Basis of Presentation
 
The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2017 and results of operations and cash flows for the three and nine months ended September 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
 
Principles of Consolidation
 
The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
 
Reclassifications
 
Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
 
Reverse Stock Split
 
The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
 
Discontinued Operations
 
In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective August 31, 2017, the Company entered into an Asset Purchase Agreement (“the Asset Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Asset Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $3.6 million for the TheraBond product line and certain other agreements between the parties and (ii) up to $112,000 for the unsold TheraBond inventory upon the Company’s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Asset Purchase Agreement. Of the $3.6 million of consideration, $300,000 is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company’s balance sheet as of September 30, 2017.
 
Additionally, effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH & Co KG.
 
The results of operations for the three and nine months ended September 30, 2017 and 2016 reflect the Company’s continuing operations.
 
Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
 
 
 
Revenue, net of returns, allowances and discounts
 
$
346
 
$
499
 
$
1,255
 
$
3,155
 
Cost of revenues
 
 
113
 
 
157
 
 
397
 
 
999
 
Gross profit
 
 
233
 
 
342
 
 
858
 
 
2,156
 
Selling, general and administrative
 
 
100
 
 
175
 
 
392
 
 
863
 
Income from discontinued operations, net of tax
 
$
133
 
$
167
 
$
466
 
$
1,293
 
 
Non-cash amortization expense of $43,000 and $74,000 is included in selling, general and administrative expense for the three months ended September 30, 2017 and 2016, respectively. Non-cash amortization expense of $185,000 and $260,000 is included in selling, general and administrative expense for the nine months ended September 30, 2017 and 2016, respectively.
 
During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $0) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
112
 
 
 
 
Consideration for intangible assets
 
 
3,600
 
 
 
 
Total Consideration
 
 
 
 
 
3,712
 
Less: Net book value of assets sold to Argentum
 
 
 
 
 
 
 
Inventory, net
 
 
(303)
 
 
 
 
Intangibles, net
 
 
(1,709)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(2,012)
 
Gain on sale of assets
 
 
 
 
$
1,700
 
 
During the nine months ended September 30, 2016, the Company recorded a gain of approximately $3.3 million (net of tax of $0) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
603
 
 
 
 
Consideration for intangible assets
 
 
3,500
 
 
 
 
Total Consideration
 
 
 
 
 
4,103
 
Less: Net book value of assets sold to BSN
 
 
 
 
 
 
 
Inventory, net
 
 
(603)
 
 
 
 
Intangibles, net
 
 
(189)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(792)
 
Gain on sale of assets
 
 
 
 
$
3,311
 
 
Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
Accounts receivable, net
 
$
164
 
$
307
 
Escrow
 
 
300
 
 
-
 
Inventory, net
 
 
-
 
 
550
 
Total current assets
 
 
464
 
 
857
 
Intangible assets, net
 
 
-
 
 
1,893
 
Total assets
 
 
464
 
 
2,750
 
 
 
 
 
 
 
 
 
Accounts payable
 
 
19
 
 
19
 
Accrued expenses and other current liabilities
 
 
18
 
 
41
 
Total current liabilities
 
$
37
 
$
60
 
 
On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (“Transition Agreement”). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum will pay the Company $200,000 for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. One-third of this compensation ($67,000) was recognized and is included in other income for the three and nine months ended September 30, 2017.
 
Significant Accounting Policies and Estimates
 
The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies in the 2016 Annual Report. Since the date of the 2016 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.  These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
 
Recent Accounting Principles
 
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.
 
There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.
 
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Going Concern
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]
2.
Going Concern
 
The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.
 
As of September 30, 2017, the Company had a cash balance of approximately $2.1 million. The Company has experienced recurring losses since its inception. The Company incurred a net loss of $13.9 million and utilized $9.8 million in cash from operations for the nine months ended September 30, 2017, and had an accumulated deficit of $138.2 million as of September 30, 2017. As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement (as defined in Note 7- Debt) as a result of the Company’s failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017, respectively. Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.
 
On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive Credit Opportunities Fund, L.P. (“Perceptive”) entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”), pursuant to which the Company agreed to pay $1,650,000 of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.
 
Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company’s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to the Company’s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company’s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.
 
The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company’s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company’s assets after the expiration of the forbearance. Such action could hinder the Company’s ability to recover the remaining carrying value of some or all of its intangible assets including goodwill that aggregated approximately $35.2 million at September 30, 2017. These factors raise substantial doubt as to the Company’s ability to continue as a going concern within one year from the date of this filing. The ability of the Company to continue as a going concern is dependent upon the Company’s successful efforts to raise sufficient capital and attain profitable operations.
 
Management is evaluating all options to raise sufficient funds to meet its outstanding debt obligations and to fund the Company’s working capital requirements. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
3.
Net Loss Per Common Share
 
Basic (loss) income per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted (loss) income per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock.
 
The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
 
 
 
Nine Months Ended Ended September 30,
 
 
 
2017
 
2016
 
Options
 
 
879,182
 
 
733,862
 
Warrants
 
 
514,561
 
 
336,541
 
Non-vested restricted stock
 
 
194,674
 
 
147,322
 
Total potentially dilutive shares
 
 
1,588,417
 
 
1,217,725
 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Termination of Merger Agreement
 9 Months Ended
Sep. 30, 2017
Disclosure Text Block Supplement [Abstract]  
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
4.
Termination of Merger Agreement
 
On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, the Company terminated this agreement.,
 
In connection with the merger agreement to acquire the business of Soluble, the Company provided Soluble with bridge loans in the form of subordinated promissory notes totaling approximately $1.4 million.  The Company advanced Soluble $1.0 million during the year ended December 31, 2016 and $350,000 on January 30, 2017.  Pursuant to the terms of the merger agreement, the amount was to be repaid in full upon termination of the agreement.  As of September 30, 2017, the Company fully reserved the amount due. As of December 31, 2016, the Company had provided for a full reserve for the amount that had been advanced to Soluble as of that date.  The Company recorded bad debt expense of $350,000 during the nine months ended September 30, 2017. This expense is included in acquisition related expense. The Company also incurred approximately $285,000 of other acquisition related expenses related to the Soluble transaction during the nine months period ended September 30, 2017. The net balance of the note receivable is $0 and is included in prepaid and other current assets as of September 30, 2017 and December 31, 2016.  See Note 12 - Subsequent Event.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]
5.
Inventory
 
Inventory consists of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Raw materials
 
$
115
 
$
135
 
Work in process
 
 
39
 
 
173
 
Finished goods
 
 
1,843
 
 
1,845
 
Less: Inventory reserve for excess and slow moving inventory
 
 
(12)
 
 
-
 
Total
 
$
1,985
 
$
2,153
 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses and Other Current Liabilities
 9 Months Ended
Sep. 30, 2017
Payables and Accruals [Abstract]  
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
6.
Accrued Expenses and Other Current Liabilities
 
Accrued expenses and other current liabilities consist of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Salaries, benefits and incentive compensation
 
$
1,713
 
$
3,007
 
Milestone payment to licensor
 
 
1,000
 
 
1,000
 
Professional fees
 
 
483
 
 
692
 
Royalty fees
 
 
200
 
 
197
 
Deferred revenue
 
 
339
 
 
181
 
Other
 
 
141
 
 
147
 
Total accrued expenses and other current liabilities
 
$
3,876
 
$
5,224
 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt
 9 Months Ended
Sep. 30, 2017
Debt Instruments [Abstract]  
Long-term Debt [Text Block]
7.
Debt
 
Senior Secured Term Loan Facility
 
On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $15.5 million. The Credit Agreement (i) has a four-year term, (ii) accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%, (iii) is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date and (iv) is secured by a first priority lien on substantially all of the Company’s assets. The payment of principal under the Credit Agreement has been deferred until January 31, 2018, see Consent and Forbearance Agreement below. The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000. The interest rate at September 30, 2017 was 11.00%.
 
In connection with the Credit Agreement, the Company incurred approximately $1.3 million of debt issuance costs. The debt issuance costs are being amortized over the term of the loan on a straight-line basis, which approximates the effective interest method. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $61,000 and $64,000, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt issuance costs of $190,000 and $209,000, respectively, which is included in interest expense.
 
In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 75,000 shares of common stock, par value of $0.001 per share at an exercise price of $55.138 per share (the “Exercise Price”) was issued to Perceptive. The Company granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. The Warrant contains a weighted average anti-dilution feature whereby the Exercise Price is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current Exercise Price. As a result, the Warrant was determined to be a derivative liability. The Warrant had an issuance date fair value of approximately $2.7 million which was recorded as a debt discount. For the three months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $144,000 and $143,000, respectively, which is included in interest expense for the periods presented. For the nine months ended September 30, 2017 and 2016, the Company recorded amortization of debt discount of $441,000 and $427,000, respectively, which is included in interest expense for the periods presented. See Note 11 – Fair Value Measurement for additional details.
 
As of September 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company’s failure to achieve $24,600,000, $27,200,000, $30,300,000, and $33,800,000 of gross revenue for the twelve-month periods ended December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017, respectively. The Company has classified the entire principal balance as a current liability in its balance sheet as of September 30, 2017 and December 31, 2016.
 
The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70. The amended and restated Warrant, as amended, contains a weighted average anti-dilution feature whereby the exercise price of the amended and restated warrant is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the current exercise price of such warrant. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. See Note 11 – Fair Value Measurement for additional details. 
Debt consists of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Principle balance
 
$
12,135
 
$
13,752
 
Unamortized debt issuance and discount costs
 
 
(1,399)
 
 
(2,211)
 
Total
 
$
10,736
 
$
11,541
 
 
Consent and Forbearance Agreement
 
Under an agreement dated January 26, 2017, as amended March 7, 2017, April 27, 2017 and August 9, 2017, the lender agreed to forbear from exercising any rights and remedies related to the default until the earlier of September 30, 2017 or the date when the lender becomes aware of any other default.
 
On August 31, 2017, in connection with the Asset Purchase Agreement with Argentum, the Company and Perceptive entered into a Consent, Forbearance and Amendment Agreement (the “Consent and Forbearance Agreement”), pursuant to which the Company agreed to pay $1,650,000 of the proceeds from the Asset Purchase Agreement to Perceptive, of which approximately $1,618,000 was applied towards the outstanding principal amount of the term loan under the credit agreement and approximately $32,000 was used to pay an early prepayment fee. This payment was made on August 31, 2017. During the three and nine months ended September 30, 2017, the Company recorded a loss on early extinguishment of debt of $214,000 related to the Consent and Forbearance Agreement. This amount consisted of the $32,000 prepayment penalty, the write-off of $129,000 of unamortized discount, and the write-off of $53,000 of unamortized debt issuance costs.
 
Under the Consent and Forbearance Agreement the lender agreed to: (a) release its liens on assets purchased by Argentum; (b) defer the commencement of the Company’s remaining principal payments until January 31, 2018, and agreed to extend the forbearance period and to forbear from exercising any rights and remedies related to the Company’s default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default. On November 7, 2017, the lender agreed to extend the forbearance period and to forbear from exercising any rights and remedies to the Company’s default of the aforementioned covenants, including the trailing twelve-month revenue as of September 30, 2017, until the earlier of December 31, 2017 or the date when the lender becomes aware of any other default.
 
The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In addition, the lender has a lien on substantially all of the Company’s assets and, as a result of the default, the lender may seek to foreclose on some or substantially all of the Company’s assets after the expiration of the forbearance.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
8.
Commitments and Contingencies
 
Agreements for Human Placental Based Products
 
Human Longevity, Inc.
 
In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The agreements grant the Company an exclusive, royalty-bearing license in CCT’s intellectual property for certain placental based products, including ECM and Biovance ®, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, HLI Cellular Therapeutics, LLC (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. In June 2017, Celularity, Inc. (“Celularity”) acquired all of the assets of HLI, including the agreements between HLI and the Company. The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. For the three months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $199,000 and $121,000, respectively, in connection with this agreement. For the nine months ended September 30, 2017 and 2016, the Company incurred royalties of approximately $591,000 and $296,000, respectively, in connection with this agreement. Approximately $199,000 and $197,000 is included in accrued expenses as of September 30, 2017 and December 31, 2016, respectively, in connection with this agreement. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term.
 
The License Agreement with Celularity is terminable on a product-by-product basis if the Company fails to meet certain minimum sales thresholds in the second year or any subsequent year of commercial sales of each licensed product. Each year of commercial sales are referred to in the License Agreement as “launch years” and the calendar period constituting each launch year for each licensed product is determined in accordance with the terms of the License Agreement. To maintain its license for Biovance, the Company must meet a minimum gross sales amount for Biovance in the second year and third year of commercial sales. If the Company fails to meet the minimum threshold in the second year of commercial sales of product, it would be able to cure such failure by making a cure payment specified in the License Agreement to Celularity; provided, however, the Company does not have the option to make a cure payment, should it fail to meet the minimum threshold for such product in the third year of commercial sales and Celularity may terminate the License Agreement with respect to such product.
 
In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product, also known as Interfyl.
 
In April 2016, the Company entered into a Supply Agreement with HLI (now Celularity), pursuant to which Celularity supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay Celularity $500,000 related to the first commercial sale of Interfyl in the flowable matrix configuration and $500,000 related to the first commercial sale of Interfyl in the particulate form. Commercial sales of both configurations occurred in September 2016, and as such, the Company recorded $1.0 million of milestone expense during the year ended December 31, 2016. The milestone has been included in accrued expenses and other current liabilities as of September 30, 2017 and December 31, 2016.
 
Contingent Consideration
 
Celleration, Inc.
 
On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. The Company agreed to pay contingent consideration of 3.5 times revenue from acquired MIST Therapy products in excess of certain revenue targets for the years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Company’s common stock. This contingent consideration was payable in two installments in March 2016 and March 2017.
 
The first installment consisted of $2.6 million of cash and approximately 98,600 shares of the Company’s common stock valued at approximately $2.6 million and was paid in March 2016. This payment was based on 3.5 times of the excess of 2015 MIST Therapy revenue of approximately $10.2 million over 2014 MIST Therapy revenue of approximately $8.7 million.
 
The second installment consisted of $675,000 of cash and approximately 100,000 shares of the Company’s common stock valued at approximately $675,000 and was paid in March 2017. This payment was based on 3.5 times of the excess of 2016 MIST Therapy revenue of approximately $10.5 million over 2015 MIST Therapy revenue of approximately $10.2 million. There are no further contingent payments due in connection with the Celleration acquisition.
 
Choice Therapeutics, Inc.
 
On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company agreed to pay contingent consideration based upon the Company achieving specific performance metrics over the three twelve-month periods, ended April 30, 2017. The Company issued approximately 130,000 shares of its common stock valued at approximately $500,000 in June 2017. There are no further contingent payments due in connection with the Choice acquisition.
 
Litigation, Claims and Assessments
 
The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2017.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
 9 Months Ended
Sep. 30, 2017
Stockholders Equity Note [Abstract]  
Stockholders Equity Note Disclosure [Text Block]
9.
Stockholders’ Equity
 
Private Placement
 
On February 27, 2017, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “Private Placement”) an aggregate of 554,000 shares of the Company’s common stock at a purchase price of $5.00 per share. The Company closed the Private Placement on the same day as it entered into the Securities Purchase Agreement and received aggregate gross proceeds of approximately $2.8 million. In connection with the Private Placement, the Company paid an aggregate of $196,000 of financial advisory fees and $40,000 of administrative fees, which were recorded as a reduction of additional paid-in capital.
 
The Securities Purchase Agreement contains a “most-favored nation” provision that provides that if the Company, during 120 days from February 27, 2017, issues or sells any common stock or common stock equivalents reasonably believed to be more favorable in terms or conditions than those in the Private Placement, then the Company must amend the terms of the Securities Purchase Agreement to give the private investors the benefit of such favorable terms or conditions. In connection with the common stock sold in the Public Offering (as defined below) and in accordance with this provision, on April 11, 2017, the Company issued an aggregate of 38,072 shares of its common stock to these investors. On June 23, 2017, the Company held its 2017 annual meeting of stockholders during which the stockholders approved the issuance of the remaining 100,429 additional shares of common stock to be issued to the investors, and, following the meeting, on June 23, 2017, the Company issued the remaining shares.
 
Underwritten Public Offering
 
On April 3, 2017, the Company closed an underwritten public offering (the “Public Offering”) of 947,325 shares of its common stock at a price to the public of $4.00 per share. The Company received aggregate gross proceeds of approximately $3.8 million. In connection with the Public Offering, the Company paid an aggregate of $365,000 of financial advisory fees and $92,000 of administrative fees, which were recorded as a reduction of additional paid-in capital. The shares of common stock were issued pursuant to the Company’s shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September 25, 2014.
 
On April 3, 2017, the Company issued warrants to purchase an aggregate of 23,684 shares of the Company’s common stock to the underwriter of this offering. These warrants are immediately exercisable, have an exercise price of $4.40, and expire on March 29, 2022. The warrants had an aggregate issuance date fair value of $78,000 which was recorded as both a debit and credit to additional paid in capital.
 
Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $21.90, the exercise price of these warrants was adjusted to the public offering price of $4.00. As of April 3, 2017, November 2012 warrants to purchase 36,230 shares of the Company’s common stock were outstanding. These warrants expire in November 2017.
 
Stock-Based Compensation
 
For the three months ended September 30, 2017 and 2016, the Company recognized $686,000 and $1.2 million of stock-based compensation expense, of which, ($1,000) and $5,000 is included in cost of revenues and $687,000 and $1.2 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. For the nine months ended September 30, 2017 and 2016, the Company recognized $1.6 million and $4.3 million of stock-based compensation expense, of which, $25,000 and $134,000 is included in cost of revenues and $1.6 million and $4.1 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. As of September 30, 2017, there was $1.4 million of unrecognized stock-based compensation expense which will be amortized over a weighted average period of 0.8 years.
 
Stock Options
 
On June 27, 2017, the Company granted non-executive employees ten-year options to purchase an aggregate of 208,050 shares of common stock at an exercise price of $3.50 per share. The aggregate grant date value of the options is $519,000. The options vest in one-fourth increments every six months over a period of two years.
 
Restricted Stock
 
During the nine months ended September 30, 2017, the Company granted an aggregate of 181,936 shares of restricted stock to employees with an aggregate grant date value of $621,000 which will be recognized proportionate to the vesting period. The shares vest as follows: (i) 66,936 shares vested on September 21, 2017, (ii) 5,000 shares vest on December 31, 2017, (iii) 50,000 shares vest on June 23, 2018, and (iv) 60,000 shares vest pursuant to the satisfaction of certain performance conditions.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party
 9 Months Ended
Sep. 30, 2017
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
10.
Related Party
 
In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then a member of the Board of Directors. During the three months ended September 30, 2017 and 2016, the Company incurred costs of approximately $28,000 and $100,000, respectively, from this vendor. During the nine months ended September 30, 2017 and 2016, the Company incurred costs of approximately $286,000 and $358,000, respectively, from this vendor. Approximately $39,000 and $102,000 is included in accounts payable related to this related party as of September 30, 2017 and December 31, 2016, respectively.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
11.
Fair Value Measurement
 
Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
 
Level 1:
Observable prices in active markets for identical assets and liabilities.
 
Level 2:
Observable inputs other than quoted prices in active markets for identical assets and liabilities.
 
Level 3:
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
 
Warrant Liabilities
 
The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70 per share. See Note 7 – Debt for additional details. In connection with the amendments of January, March, April and June 2017, the Company recomputed the fair value of the original warrant and amended warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 65.33%-78.98%, risk-free rate of 1.49%-1.95%, expected term of 3.34-5.00 years, and expected dividends of 0.00%. As a result, the Company recorded warrant modification expense of $0 and $803,000 during the three and nine months ended September 30, 2017, respectively, which represents the incremental value of the amended warrant as compared to the original warrant, both valued as of the respective amendment dates.
 
On September 30, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 246,231 shares of common stock as $419,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 72.63%-131.85%, risk-free rate of 0.96%-1.77%, expected term of 0.10-4.32 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $35,000 and $404,000 during the three and nine months ended September 30, 2017, respectively.
 
The issuance of common stock in connection with the Private Placement and Public Offering triggered an adjustment to the exercise price of certain warrants originally issued in November 2012 from $55.10 per share to $5.00 per share to $4.00 per share with a corresponding adjustment to the number of shares underlying such warrants from 6,629 shares to 29,034 shares to 36,231 shares. The impact of such adjustment is included in the change in fair value of the warrant liabilities during the nine months ended September 30, 2017.
 
Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.
 
The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands):
 
 
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
Warrant Liabilities
 
 
 
 
 
 
 
Beginning balance
 
$
20
 
$
861
 
Change in fair value of warrant liability
 
 
(404)
 
 
(797)
 
Warrant modification expense
 
 
803
 
 
-
 
Ending balance
 
$
419
 
$
64
 
 
 
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
 
$
1,816
 
$
17,028
 
Payments of contingent consideration
 
 
(1,851)
 
 
(5,147)
 
Change in fair value of contingent consideration
 
 
35
 
 
(8,634)
 
Ending balance
 
$
-
 
$
3,247
 
  
Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):
 
 
 
September 30, 2017
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
419
 
Total liabilities
 
$
-
 
$
-
 
$
419
 
 
 
 
December 31, 2016
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
20
 
Contingent consideration
 
 
-
 
 
-
 
 
1,816
 
Total liabilities
 
$
-
 
$
-
 
$
1,836
 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Event
 9 Months Ended
Sep. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
12.
Subsequent Event
 
The Company advanced Soluble $1.4 million, $1.0 million during the year ended December 31, 2016 and $350,000 on January 30, 2017. 
 
On October 27, 2017, the Company received $1 million under an agreement with Soluble in connection with amounts advanced to Soluble by the Company. With the receipt of this $1 million, the Company acknowledged that all amounts due to the Company from Soluble are paid in full.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
 
The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2017 and results of operations and cash flows for the three and nine months ended September 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]
Principles of Consolidation
 
The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]
Reclassifications
 
Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Reverse Stock Split policy [Policy Text Block]
Reverse Stock Split
 
The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
Discontinued Operations, Policy [Policy Text Block]
Discontinued Operations
 
In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective August 31, 2017, the Company entered into an Asset Purchase Agreement (“the Asset Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Asset Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $3.6 million for the TheraBond product line and certain other agreements between the parties and (ii) up to $112,000 for the unsold TheraBond inventory upon the Company’s completion of its obligations to deliver all remaining and qualifying unsold TheraBond inventory, as specified in the Asset Purchase Agreement. Of the $3.6 million of consideration, $300,000 is deposited in an indemnity escrow account under standard terms and conditions. This amount is classified under current assets of discontinued operations on the Company’s balance sheet as of September 30, 2017.
 
Additionally, effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH & Co KG.
 
The results of operations for the three and nine months ended September 30, 2017 and 2016 reflect the Company’s continuing operations.
 
Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
 
 
 
Revenue, net of returns, allowances and discounts
 
$
346
 
$
499
 
$
1,255
 
$
3,155
 
Cost of revenues
 
 
113
 
 
157
 
 
397
 
 
999
 
Gross profit
 
 
233
 
 
342
 
 
858
 
 
2,156
 
Selling, general and administrative
 
 
100
 
 
175
 
 
392
 
 
863
 
Income from discontinued operations, net of tax
 
$
133
 
$
167
 
$
466
 
$
1,293
 
 
Non-cash amortization expense of $43,000 and $74,000 is included in selling, general and administrative expense for the three months ended September 30, 2017 and 2016, respectively. Non-cash amortization expense of $185,000 and $260,000 is included in selling, general and administrative expense for the nine months ended September 30, 2017 and 2016, respectively.
 
During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $0) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
112
 
 
 
 
Consideration for intangible assets
 
 
3,600
 
 
 
 
Total Consideration
 
 
 
 
 
3,712
 
Less: Net book value of assets sold to Argentum
 
 
 
 
 
 
 
Inventory, net
 
 
(303)
 
 
 
 
Intangibles, net
 
 
(1,709)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(2,012)
 
Gain on sale of assets
 
 
 
 
$
1,700
 
 
During the nine months ended September 30, 2016, the Company recorded a gain of approximately $3.3 million (net of tax of $0) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
603
 
 
 
 
Consideration for intangible assets
 
 
3,500
 
 
 
 
Total Consideration
 
 
 
 
 
4,103
 
Less: Net book value of assets sold to BSN
 
 
 
 
 
 
 
Inventory, net
 
 
(603)
 
 
 
 
Intangibles, net
 
 
(189)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(792)
 
Gain on sale of assets
 
 
 
 
$
3,311
 
 
Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
Accounts receivable, net
 
$
164
 
$
307
 
Escrow
 
 
300
 
 
-
 
Inventory, net
 
 
-
 
 
550
 
Total current assets
 
 
464
 
 
857
 
Intangible assets, net
 
 
-
 
 
1,893
 
Total assets
 
 
464
 
 
2,750
 
 
 
 
 
 
 
 
 
Accounts payable
 
 
19
 
 
19
 
Accrued expenses and other current liabilities
 
 
18
 
 
41
 
Total current liabilities
 
$
37
 
$
60
 
 
On August 31, 2017, the Company entered into a ninety-day transition services agreement with Argentum (“Transition Agreement”). Under the Transition Agreement, the Company is required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the TheraBond product line to Argentum, as specified in the Transition Agreement. As compensation, Argentum will pay the Company $200,000 for the services completed during the period from the closing of the purchase for three months ended November 30, 2017. One-third of this compensation ($67,000) was recognized and is included in other income for the three and nine months ended September 30, 2017.
Significant Accounting Policies and Estimates [Policy Text Block]
Significant Accounting Policies and Estimates
 
The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies in the 2016 Annual Report. Since the date of the 2016 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.  These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Principles
 
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.
 
There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.
 
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Tables)
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Disposal Groups, Including Discontinued Operations [Table Text Block]
Summarized operating results of discontinued operations for the three and nine months ended September 30, 2017 and 2016 are presented in the following table (in thousands):
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
 
 
 
Revenue, net of returns, allowances and discounts
 
$
346
 
$
499
 
$
1,255
 
$
3,155
 
Cost of revenues
 
 
113
 
 
157
 
 
397
 
 
999
 
Gross profit
 
 
233
 
 
342
 
 
858
 
 
2,156
 
Selling, general and administrative
 
 
100
 
 
175
 
 
392
 
 
863
 
Income from discontinued operations, net of tax
 
$
133
 
$
167
 
$
466
 
$
1,293
 
 
Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
Accounts receivable, net
 
$
164
 
$
307
 
Escrow
 
 
300
 
 
-
 
Inventory, net
 
 
-
 
 
550
 
Total current assets
 
 
464
 
 
857
 
Intangible assets, net
 
 
-
 
 
1,893
 
Total assets
 
 
464
 
 
2,750
 
 
 
 
 
 
 
 
 
Accounts payable
 
 
19
 
 
19
 
Accrued expenses and other current liabilities
 
 
18
 
 
41
 
Total current liabilities
 
$
37
 
$
60
 
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]
During the three and nine months ended September 30, 2017, the Company recorded a gain of approximately $1.7 million (net of tax of $0) on the sale of the assets related to the purchase agreement with Argentum, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
112
 
 
 
 
Consideration for intangible assets
 
 
3,600
 
 
 
 
Total Consideration
 
 
 
 
 
3,712
 
Less: Net book value of assets sold to Argentum
 
 
 
 
 
 
 
Inventory, net
 
 
(303)
 
 
 
 
Intangibles, net
 
 
(1,709)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(2,012)
 
Gain on sale of assets
 
 
 
 
$
1,700
 
 
During the nine months ended September 30, 2016, the Company recorded a gain of approximately $3.3 million (net of tax of $0) on the sale of the assets related to the purchase agreement with BSN, pursuant to the following (in thousands):
 
Proceeds from sale
 
 
 
 
 
 
 
Consideration for inventory
 
$
603
 
 
 
 
Consideration for intangible assets
 
 
3,500
 
 
 
 
Total Consideration
 
 
 
 
 
4,103
 
Less: Net book value of assets sold to BSN
 
 
 
 
 
 
 
Inventory, net
 
 
(603)
 
 
 
 
Intangibles, net
 
 
(189)
 
 
 
 
Total net book value of assets
 
 
 
 
 
(792)
 
Gain on sale of assets
 
 
 
 
$
3,311
 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
 
 
 
Nine Months Ended Ended September 30,
 
 
 
2017
 
2016
 
Options
 
 
879,182
 
 
733,862
 
Warrants
 
 
514,561
 
 
336,541
 
Non-vested restricted stock
 
 
194,674
 
 
147,322
 
Total potentially dilutive shares
 
 
1,588,417
 
 
1,217,725
 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory (Tables)
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventory consists of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Raw materials
 
$
115
 
$
135
 
Work in process
 
 
39
 
 
173
 
Finished goods
 
 
1,843
 
 
1,845
 
Less: Inventory reserve for excess and slow moving inventory
 
 
(12)
 
 
-
 
Total
 
$
1,985
 
$
2,153
 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses and Other Current Liabilities (Tables)
 9 Months Ended
Sep. 30, 2017
Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]
Accrued expenses and other current liabilities consist of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Salaries, benefits and incentive compensation
 
$
1,713
 
$
3,007
 
Milestone payment to licensor
 
 
1,000
 
 
1,000
 
Professional fees
 
 
483
 
 
692
 
Royalty fees
 
 
200
 
 
197
 
Deferred revenue
 
 
339
 
 
181
 
Other
 
 
141
 
 
147
 
Total accrued expenses and other current liabilities
 
$
3,876
 
$
5,224
 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt (Tables)
 9 Months Ended
Sep. 30, 2017
Debt Instruments [Abstract]  
Schedule of Debt [Table Text Block]
Debt consists of the following (in thousands):
 
 
 
September 30,
 
December 31,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Principle balance
 
$
12,135
 
$
13,752
 
Unamortized debt issuance and discount costs
 
 
(1,399)
 
 
(2,211)
 
Total
 
$
10,736
 
$
11,541
 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands):
 
 
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
Warrant Liabilities
 
 
 
 
 
 
 
Beginning balance
 
$
20
 
$
861
 
Change in fair value of warrant liability
 
 
(404)
 
 
(797)
 
Warrant modification expense
 
 
803
 
 
-
 
Ending balance
 
$
419
 
$
64
 
 
 
 
Nine Months Ended September 30,
 
 
 
2017
 
2016
 
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
 
$
1,816
 
$
17,028
 
Payments of contingent consideration
 
 
(1,851)
 
 
(5,147)
 
Change in fair value of contingent consideration
 
 
35
 
 
(8,634)
 
Ending balance
 
$
-
 
$
3,247
 
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):
 
 
 
September 30, 2017
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
419
 
Total liabilities
 
$
-
 
$
-
 
$
419
 
 
 
 
December 31, 2016
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
20
 
Contingent consideration
 
 
-
 
 
-
 
 
1,816
 
Total liabilities
 
$
-
 
$
-
 
$
1,836
 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue, net of returns, allowances and discounts $ 346 $ 499 $ 1,255 $ 3,155
Cost of revenues 113 157 397 999
Gross profit 233 342 858 2,156
Selling, general and administrative 100 175 392 863
Income from discontinued operations, net of tax $ 133 $ 167 $ 466 $ 1,293
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Details 1) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Proceeds from sale        
Consideration for inventory     $ 112 $ 603
Consideration for intangible assets     3,600 3,500
Total Consideration     3,712 4,103
Net book value of assets sold        
Inventory, net $ (303) $ (603) (303) (603)
Intangibles, net (1,709) (189) (1,709) (189)
Total net book value of assets (2,012) (792) (2,012) (792)
Gain on sale of assets $ 1,700 $ 0 $ 1,700 $ 3,311
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Details 2) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Accounts receivable, net $ 164 $ 307
Escrow 300 0
Inventory, net 0 550
Total current assets 464 857
Intangible assets, net 0 1,893
Total assets 464 2,750
Accounts payable 19 19
Accrued expenses and other current liabilities 18 41
Total current liabilities $ 37 $ 60
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Description of Business and Basis of Presentation (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 05, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Aug. 31, 2017
Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax   $ 1,700,000 $ 0 $ 1,700,000 $ 3,311,000    
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation   $ 0 0 $ 0 0    
Disposal Group, Including Discontinued Operation, Maximum Amount To be Received for Unsold Inventory           $ 112,000  
Common Stock, Par or Stated Value Per Share   $ 0.001   $ 0.001     $ 0.001
Disposal Group, Including Discontinued Operation, Consideration           3,600,000  
Disposal Group, Including Discontinued Operation, Escrow Deposit, Current   $ 300,000   $ 300,000     $ 0
Accrued Fees and Other Revenue Receivable           $ 200,000  
Other Income   67,000 100,000 67,000 100,000    
Argentum Medical, LLC [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Other Income   67,000   67,000      
Subsequent Event [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Stockholders' Equity, Reverse Stock Split 1-for-10            
Common Stock, Par or Stated Value Per Share $ 0.001            
Purchase Agreement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax   1,700,000 3,300,000 1,700,000 3,300,000    
Selling, General and Administrative Expenses [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Amortization of Intangible Assets   $ 43,000 $ 74,000 $ 185,000 $ 260,000    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Going Concern (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Net Income (Loss) Attributable to Parent, Total   $ (2,700,000) $ (8,588,000) $ (13,900,000) $ (11,098,000)        
Net Cash Provided by (Used in) Operating Activities       (9,799,000) (14,034,000)        
Retained Earnings (Accumulated Deficit), Total   (138,203,000)   (138,203,000)       $ (124,303,000)  
Cash and Cash Equivalents, at Carrying Value, Total   2,106,000 10,701,000 2,106,000 10,701,000     5,580,000 $ 26,080,000
Intangible Assets, Net (Including Goodwill)   35,200,000   35,200,000          
Gross Revenue       33,800,000   $ 30,300,000 $ 27,200,000 $ 24,600,000  
Gain (Loss) on Extinguishment of Debt   (214,000) $ (373,000) (214,000) (373,000)        
Amortization of Debt Discount (Premium)       631,000 $ 636,000        
Senior Secured Debt [Member]                  
Proceeds from Divestiture of Businesses and Interests in Affiliates $ 1,650,000                
Repayments of Debt 1,618,000                
Payments for Prepayment Penalties $ 32,000                
Gain (Loss) on Extinguishment of Debt   214,000   214,000          
Prepayment Penalty On Early Extinguishment Of Debt   32,000   32,000          
Amortization of Debt Discount (Premium)   129,000   129,000          
Write off of Deferred Debt Issuance Cost   $ 53,000   $ 53,000          
Debt Instrument, Debt Default, Description of Violation or Event of Default the Companys default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default.                
Debt Instrument, Debt Default, Amount $ 2,000,000                
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Common Share (Details) - shares
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,588,417 1,217,725
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 879,182 733,862
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 514,561 336,541
Non-vested Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 194,674 147,322
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Termination of Merger Agreement (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jan. 30, 2017
Dec. 31, 2016
Oct. 05, 2016
Long-term Debt, Gross $ 12,135,000   $ 12,135,000     $ 13,752,000  
Provision for Doubtful Accounts     169,000 $ 37,000      
Business Combination, Acquisition Related Costs 0 $ 715,000 635,000 $ 819,000      
Bridge Loan [Member]              
Long-term Debt, Gross             $ 1,400,000
Debt Instrument, Face Amount         $ 350,000 $ 1,000,000  
Provision for Doubtful Accounts     350,000        
Business Combination, Acquisition Related Costs     285,000        
Prepaid Expenses and Other Current Assets [Member]              
Notes Receivable, Current $ 0   $ 0        
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Inventory [Line Items]    
Raw materials $ 115 $ 135
Work in process 39 173
Finished goods 1,843 1,845
Less: Inventory reserve for excess and slow moving inventory (12) 0
Total $ 1,985 $ 2,153
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Accrued Liabilities Current Line Items [Line Items]    
Salaries, benefits and incentive compensation $ 1,713 $ 3,007
Milestone payment to licensor 1,000 1,000
Professional fees 483 692
Royalty fees 200 197
Deferred revenue 339 181
Other 141 147
Total accrued expenses and other current liabilities $ 3,876 $ 5,224
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Debt Instrument [Line Items]    
Principle balance $ 12,135 $ 13,752
Unamortized debt issuance and discount costs (1,399) (2,211)
Total $ 10,736 $ 11,541
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 01, 2017
Dec. 31, 2015
May 29, 2015
Nov. 30, 2012
Debt Instrument [Line Items]                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                   210,000      
Common Stock, Par or Stated Value Per Share   $ 0.001   $ 0.001       $ 0.001          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 55.138   $ 55.138           $ 4.70     $ 55.10
Derivative Liability   $ 419,000 $ 64,000 $ 419,000 $ 64,000     $ 20,000 $ 64,000   $ 861,000    
Amortization of Debt Discount (Premium)       $ 631,000 636,000                
Warrant Expiration Period       five-year warrant                  
Common Stock Purchased By Warrants Issued       75,000                  
Exit fee payment, Credit Agreement Description       The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000.                  
Gain (Loss) on Extinguishment of Debt   (214,000) (373,000) $ (214,000) (373,000)                
Revenues   4,901,000 4,375,000 14,108,000 11,851,000                
Fair Value, Inputs, Level 3 [Member]                          
Debt Instrument [Line Items]                          
Derivative Liability   419,000   419,000       $ 20,000          
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]                          
Debt Instrument [Line Items]                          
Derivative Liability   2,700,000   2,700,000                  
Interest Expense [Member]                          
Debt Instrument [Line Items]                          
Amortization of Financing Costs   61,000 64,000 190,000 209,000                
Amortization of Debt Discount (Premium)   144,000 $ 143,000 441,000 $ 427,000                
Senior Secured Debt [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Face Amount                       $ 15,500,000  
Debt Issuance Costs1       1,300,000                  
Amortization of Debt Discount (Premium)   129,000   $ 129,000                  
Debt Instrument, Interest Rate Terms       accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%                  
Debt Instrument, Term               4 years          
Debt Instrument, Payment Terms               is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date          
Debt Instrument, Maturity Date, Description               The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000          
Payments for Prepayment Penalties $ 32,000                        
Proceeds from Divestiture of Businesses and Interests in Affiliates 1,650,000                        
Repayments of Debt $ 1,618,000                        
Gain (Loss) on Extinguishment of Debt   214,000   $ 214,000                  
Prepayment Penalty On Early Extinguishment Of Debt   32,000   32,000                  
Write off of Deferred Debt Issuance Cost   $ 53,000   $ 53,000                  
Debt Instrument, Debt Default, Description of Violation or Event of Default the Companys default of a covenant pertaining to (i) trailing twelve-month revenue under the Credit Agreement as of (A) September 30, 2016, (B) December 31, 2016 (C) March 31, 2017 and (D) June 30, 2017 and (ii) failure to maintain on a consolidated basis, a monthly minimum cash balance of at least $2,000,000, until the earlier of October 13, 2017 or the date when the lender becomes aware of any other default.                        
Debt Instrument, Interest Rate During Period       11.00%                  
Credit Agreement [Member]                          
Debt Instrument [Line Items]                          
Revenues           $ 33,800,000 $ 30,300,000 $ 27,200,000 $ 24,600,000        
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2017
Mar. 31, 2017
Sep. 30, 2016
Mar. 31, 2016
Jun. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Commitments And Contingencies [Line Items]                
Royalty Expense $ 200,000   $ 271,000     $ 593,000 $ 746,000  
Accrued Liabilities, Current 3,876,000         3,876,000   $ 5,224,000
Revenues 4,901,000   4,375,000     14,108,000 11,851,000  
Installment One [Member] | Two Thousand Fifteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues       $ 10,200,000        
Installment One [Member] | Two Thousand Fourteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues       $ 8,700,000        
Installment two [Member]                
Commitments And Contingencies [Line Items]                
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets   3.5            
Installment two [Member] | Two Thousand Fifteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues   $ 10,200,000            
Installment two [Member] | Two Thousand Sixteen MIST Therapy [Member]                
Commitments And Contingencies [Line Items]                
Revenues   10,500,000            
Human Longevity, Inc [Member]                
Commitments And Contingencies [Line Items]                
Royalty Expense 199,000   121,000     591,000 296,000  
Accrued Liabilities, Current 199,000   $ 197,000     199,000 $ 197,000  
Revenue Recognition, Milestone Method, Milestone Expenses           1,000,000    
Human Longevity, Inc [Member] | First Commercial Sale [Member]                
Commitments And Contingencies [Line Items]                
Contractual Obligation, Due in Next Twelve Months 500,000         500,000    
Human Longevity, Inc [Member] | Second Commercial Sale [Member]                
Commitments And Contingencies [Line Items]                
Contractual Obligation, Due in Next Twelve Months $ 500,000         $ 500,000    
Contingent Consideration [Member] | Installment One [Member]                
Commitments And Contingencies [Line Items]                
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets       3.5        
Payments to Acquire Businesses, Gross       $ 2,600,000        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares       98,600        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned       $ 2,600,000        
Contingent Consideration [Member] | Installment two [Member]                
Commitments And Contingencies [Line Items]                
Payments to Acquire Businesses, Gross   $ 675,000            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares   100,000            
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned   $ 675,000            
Choice Therapeutics, Inc. [Member]                
Commitments And Contingencies [Line Items]                
Business Combination, Contingent Consideration, Liability         $ 500,000      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares         130,000      
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 11, 2017
Apr. 03, 2017
Jun. 27, 2017
Feb. 27, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 23, 2017
Jun. 01, 2017
Dec. 31, 2016
Dec. 31, 2015
Nov. 30, 2012
Nov. 08, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Allocated Share-based Compensation Expense         $ 686,000 $ 1,200,000 $ 1,600,000 $ 4,300,000            
Proceeds from Issuance of Private Placement       $ 2,800,000                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                   210,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 55.138   $ 55.138     $ 4.70     $ 55.10  
Derivative Liability         $ 419,000 64,000 $ 419,000 64,000     $ 20,000 $ 861,000    
Cost of Sales [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Allocated Share-based Compensation Expense         1,000 5,000 25,000 134,000            
Selling, General and Administrative Expenses [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Allocated Share-based Compensation Expense         687,000 $ 1,200,000 $ 1,600,000 $ 4,100,000            
Private Placement [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Stock Issued During Period, Shares, New Issues       554,000                    
Share Price       $ 5.00                    
Payments for Other Fees       $ 196,000                    
Payment for Administrative Fees       $ 40,000                    
Underwritten Public Offering [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Stock Issued During Period, Shares, New Issues   947,325                        
Share Price   $ 4.00                       $ 4.00
Payments for Other Fees   $ 365,000                        
Payment for Administrative Fees   92,000                        
Stock Issued During Period, Value, New Issues   $ 3,800,000                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   23,684                        
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 4.40                       $ 21.90
Class of Warrant or Right, Expiration Date   Mar. 29, 2022                        
Securities Purchase Agreement [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Stock Issued During Period, Shares, New Issues 38,072                          
Securities Purchase Agreement [Member] | Common Stock [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Common Stock, Capital Shares Reserved for Future Issuance                 100,429          
Non Executive Employees [Member] | Underwritten Public Offering [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     208,050                      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price     $ 3.50                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value     $ 519,000                      
Restricted Stock Units (RSUs) [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period             621,000              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value             $ 181,936              
Restricted Stock [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total         $ 1,400,000   $ 1,400,000              
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition             9 months 18 days              
Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period             66,936              
Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period             5,000              
Restricted Stock [Member] | Share-based Compensation Award, Tranche Three [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period             50,000              
Restricted Stock [Member] | Deferred Compensation, Share-based Payments [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period             60,000              
Warrant [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Derivative Liability   $ 78,000                        
November 2012 Warrants [Member]                            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   36,230                        
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Related Party Transaction [Line Items]          
Related Party Transaction, Expenses from Transactions with Related Party $ 28,000 $ 100,000 $ 286,000 $ 358,000  
Accounts Payable, Related Parties $ 39,000   $ 39,000   $ 102,000
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Beginning balance     $ 20 $ 861
Change in fair value of warrant liability     (404) (797)
Warrant modification expense $ 0 $ 0 803 0
Ending balance 419 64 419 64
Contingent Consideration [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Beginning balance     1,816 17,028
Payments of contingent consideration     (1,851) (5,147)
Change in fair value of warrant liability     35 (8,634)
Ending balance $ 0 $ 3,247 $ 0 $ 3,247
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement (Details 1) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2015
Liabilities:        
Warrant liabilities $ 419 $ 20 $ 64 $ 861
Fair Value, Inputs, Level 1 [Member]        
Liabilities:        
Warrant liabilities 0 0    
Contingent consideration   0    
Total liabilities 0 0    
Fair Value, Inputs, Level 2 [Member]        
Liabilities:        
Warrant liabilities 0 0    
Contingent consideration   0    
Total liabilities 0 0    
Fair Value, Inputs, Level 3 [Member]        
Liabilities:        
Warrant liabilities 419 20    
Contingent consideration   1,816    
Total liabilities $ 419 $ 1,836    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 26, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 01, 2017
Dec. 31, 2016
Dec. 31, 2015
Nov. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative Liability   $ 419 $ 64 $ 419 $ 64   $ 20 $ 861  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 55.138   $ 55.138   $ 4.70     $ 55.10
Fair Value Adjustment of Warrants   $ (35) (135) $ (404) (797)        
Restructuring Costs   0 $ 0 $ 803 $ 0        
Class of Warrant or Right, Outstanding                 6,629
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           210,000      
Common Stock [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Warrants To Purchase Common Stock       246,231          
Maximum [Member] | Private Placement 2017 [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 4.00
Class of Warrant or Right, Outstanding                 36,231
Minimum [Member] | Private Placement 2017 [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 5.00
Class of Warrant or Right, Outstanding                 29,034
Fair Value, Inputs, Level 3 [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative Liability   $ 419   $ 419     $ 20    
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Fair Value Assumptions, Expected Dividend Rate 0.00%     0.00%          
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Fair Value Assumptions, Expected Volatility Rate 78.98%     131.85%          
Fair Value Assumptions, Risk Free Interest Rate 1.95%     1.77%          
Fair Value Assumptions, Expected Term 5 years     4 years 3 months 25 days          
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Fair Value Assumptions, Expected Volatility Rate 65.33%     72.63%          
Fair Value Assumptions, Risk Free Interest Rate 1.49%     0.96%          
Fair Value Assumptions, Expected Term 3 years 4 months 2 days     1 month 6 days          
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Event (Details Textual) - Soluble Systems, LLC [Member] - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Oct. 27, 2017
Jan. 30, 2017
Sep. 30, 2017
Dec. 31, 2016
Subsequent Event [Line Items]        
Payments to Fund Long-term Loans to Related Parties   $ 350,000 $ 1,400,000 $ 1,000,000
Subsequent Event [Member]        
Subsequent Event [Line Items]        
Proceeds from Collection of Long-term Loans to Related Parties $ 1,000,000      
EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 119 240 1 false 47 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.alliqua.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.alliqua.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.alliqua.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.alliqua.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] Sheet http://www.alliqua.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.alliqua.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 107 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 7 false false R8.htm 108 - Disclosure - Going Concern Sheet http://www.alliqua.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 109 - Disclosure - Net Loss Per Common Share Sheet http://www.alliqua.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 9 false false R10.htm 110 - Disclosure - Termination of Merger Agreement Sheet http://www.alliqua.com/role/TerminationOfMergerAgreement Termination of Merger Agreement Notes 10 false false R11.htm 111 - Disclosure - Inventory Sheet http://www.alliqua.com/role/Inventory Inventory Notes 11 false false R12.htm 112 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.alliqua.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 113 - Disclosure - Debt Sheet http://www.alliqua.com/role/Debt Debt Notes 13 false false R14.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.alliqua.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.alliqua.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 116 - Disclosure - Related Party Sheet http://www.alliqua.com/role/RelatedParty Related Party Notes 16 false false R17.htm 117 - Disclosure - Fair Value Measurement Sheet http://www.alliqua.com/role/FairValueMeasurement Fair Value Measurement Notes 17 false false R18.htm 118 - Disclosure - Subsequent Event Sheet http://www.alliqua.com/role/SubsequentEvent Subsequent Event Notes 18 false false R19.htm 119 - Disclosure - Description of Business and Basis of Presentation (Policies) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies Description of Business and Basis of Presentation (Policies) Policies 19 false false R20.htm 120 - Disclosure - Description of Business and Basis of Presentation (Tables) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationTables Description of Business and Basis of Presentation (Tables) Tables http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentation 20 false false R21.htm 121 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.alliqua.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.alliqua.com/role/NetLossPerCommonShare 21 false false R22.htm 122 - Disclosure - Inventory (Tables) Sheet http://www.alliqua.com/role/InventoryTables Inventory (Tables) Tables http://www.alliqua.com/role/Inventory 22 false false R23.htm 123 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.alliqua.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.alliqua.com/role/AccruedExpensesAndOtherCurrentLiabilities 23 false false R24.htm 124 - Disclosure - Debt (Tables) Sheet http://www.alliqua.com/role/DebtTables Debt (Tables) Tables http://www.alliqua.com/role/Debt 24 false false R25.htm 125 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.alliqua.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.alliqua.com/role/FairValueMeasurement 25 false false R26.htm 126 - Disclosure - Description of Business and Basis of Presentation (Details) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails Description of Business and Basis of Presentation (Details) Details http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationTables 26 false false R27.htm 127 - Disclosure - Description of Business and Basis of Presentation (Details 1) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails1 Description of Business and Basis of Presentation (Details 1) Details http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationTables 27 false false R28.htm 128 - Disclosure - Description of Business and Basis of Presentation (Details 2) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails2 Description of Business and Basis of Presentation (Details 2) Details http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationTables 28 false false R29.htm 129 - Disclosure - Description of Business and Basis of Presentation (Details Textual) Sheet http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsTextual Description of Business and Basis of Presentation (Details Textual) Details http://www.alliqua.com/role/DescriptionOfBusinessAndBasisOfPresentationTables 29 false false R30.htm 130 - Disclosure - Going Concern (Details Textual) Sheet http://www.alliqua.com/role/GoingConcernDetailsTextual Going Concern (Details Textual) Details http://www.alliqua.com/role/GoingConcern 30 false false R31.htm 131 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.alliqua.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://www.alliqua.com/role/NetLossPerCommonShareTables 31 false false R32.htm 132 - Disclosure - Termination of Merger Agreement (Details Textual) Sheet http://www.alliqua.com/role/TerminationOfMergerAgreementDetailsTextual Termination of Merger Agreement (Details Textual) Details http://www.alliqua.com/role/TerminationOfMergerAgreement 32 false false R33.htm 133 - Disclosure - Inventory (Details) Sheet http://www.alliqua.com/role/InventoryDetails Inventory (Details) Details http://www.alliqua.com/role/InventoryTables 33 false false R34.htm 134 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.alliqua.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.alliqua.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables 34 false false R35.htm 135 - Disclosure - Debt (Details) Sheet http://www.alliqua.com/role/DebtDetails Debt (Details) Details http://www.alliqua.com/role/DebtTables 35 false false R36.htm 136 - Disclosure - Debt (Details Textual) Sheet http://www.alliqua.com/role/DebtDetailsTextual Debt (Details Textual) Details http://www.alliqua.com/role/DebtTables 36 false false R37.htm 137 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.alliqua.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.alliqua.com/role/CommitmentsAndContingencies 37 false false R38.htm 138 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.alliqua.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.alliqua.com/role/StockholdersEquity 38 false false R39.htm 139 - Disclosure - Related Party (Details Textual) Sheet http://www.alliqua.com/role/RelatedPartyDetailsTextual Related Party (Details Textual) Details http://www.alliqua.com/role/RelatedParty 39 false false R40.htm 140 - Disclosure - Fair Value Measurement (Details) Sheet http://www.alliqua.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://www.alliqua.com/role/FairValueMeasurementTables 40 false false R41.htm 141 - Disclosure - Fair Value Measurement (Details 1) Sheet http://www.alliqua.com/role/FairValueMeasurementDetails1 Fair Value Measurement (Details 1) Details http://www.alliqua.com/role/FairValueMeasurementTables 41 false false R42.htm 142 - Disclosure - Fair Value Measurement (Details Textual) Sheet http://www.alliqua.com/role/FairValueMeasurementDetailsTextual Fair Value Measurement (Details Textual) Details http://www.alliqua.com/role/FairValueMeasurementTables 42 false false R43.htm 143 - Disclosure - Subsequent Event (Details Textual) Sheet http://www.alliqua.com/role/SubsequentEventDetailsTextual Subsequent Event (Details Textual) Details http://www.alliqua.com/role/SubsequentEvent 43 false false All Reports Book All Reports alqa-20170930.xml alqa-20170930.xsd alqa-20170930_cal.xml alqa-20170930_def.xml alqa-20170930_lab.xml alqa-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 62 0001144204-17-057623-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-057623-xbrl.zip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